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Executive Summary 
Private pharmacies or shops are the source of 60% of the drugs bought to treat suspected 
cases of malaria.  At the same time 59% of children fail to be treated within 24 hours of 
onset. The private sector is the primary source for antimalarials, but parents and carers are 
failing to administer those drugs sufficiently early to minimise morbidity and mortality.   
This review focused on the way in which antimalarial drugs reach the patient.  It also 
examined ways in which the delivery system could be improved and how the private facilities 
can become more effective sources of both drugs and advice.  It has found that there are 
many problems with the way that drugs are distributed.  Many unregistered drugs are readily 
available, and poor storage conditions are likely to reduce the efficacy of drugs even if they 
were of good quality at the time of manufacture.  For many people the cost of even the 
cheapest antimalarial is an issue and purchase of part doses is common.  The knowledge of 
the staff in pharmacies is poor and in shops woefully inadequate.  Nonetheless most people 
use shops and private pharmacies as their source for drugs. 
There are two overarching requirements:  
• First of all the needs and capabilities of the private sector must always be taken into 
account before any decision is made about how to make antimalarials more available.   
• Secondly, educating the staff and public will only be achieved through a subtle 
communications package regularly repeated and brought up to date.  For example we 
found that many workers in Part II pharmacies remain in post for no more than one 
year.  Unlike their counterparts in the public sector, staff in the private sector do not 
find incentives in attending training courses.  Staff in the public sector spend so much 
time on courses that their time to actually implement what they have learned is 
limited.  To reach the private sector staff will require subtler and more cost effective 
methods. 
The report is full of detailed recommendations for the improvement of the supply systems 
and for educating both staff and public.   
Section 3 covers issues concerning the quality of drugs, especially the control of 
unregistered drugs and the usefulness of minilabs to assure quality at point of entry and their 
limited use for testing drugs within the country.  The section also makes recommendations 
on how to improve the poor quality of storage, handling and distribution of drugs. 
Section 4 considers labelling and instructions on drugs, which generally are poor. For 
example there is no requirement to print in Swahili despite the fact that Swahili is the primary 
language and often the only language for many rural people. 
Section 5 proposes ways in which general shops can be made more effective as 
outlets for drugs, and considers making both SP and amodiaquine available in shops. 
Section 6 reviews the steps necessary for the control of restricted products.  It 
concludes that all those involved in inspection need to be supplied with lists of which items 
may be held by which types of shop and that inspectors must be assisted in buying suitable 
transport. Inspectors should not go out of their way to try and prevent Part I drugs being 
stocked at Part II outlets, unless supply of antimalarials to the public facilities can be 
guaranteed, because the public sector often relies on the Part II outlets as a source of drugs 
when the public sector is out of stock, and enforcing compliance to the letter of the law is too 
onerous for the limited number of inspectors available. 
Section 7 reviews the functioning of private laboratories and finds considerable cause 
for concern in some of them.  There is particular concern over the way parenteral procedures 
are carried out and a more detailed assessment needs to be made of how these procedures 
are performed.  This should be the subject of a separate consultancy in the near future. 
ix  
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Section 8 assesses the ways in which consumer and retailer knowledge can be 
improved and concludes that the task of developing a coherent communications strategy 
needs to be contracted out to a professional communications organisation. 
Section 9 describes the need to reduce the price paid for antimalarials and proposes 
that a campaign be launched to force the manufacturers to reduce their prices and especially 
to reduce the markups made by wholesalers.  At the same time the government should 
drastically reduce the price of antimalarials in public facilities where at present they are sold 
(including the consultation fee) for eight times the price paid by the government.  
Section 10 considers the role of training and concludes that while basic training is a 
prerequisite, training itself is not the mechanism to be used to convey the information and 
skills needed.  The reason for this is that there is already so much training being carried out 
that responsible officers hardly have time to carry out their duties.  In addition, for the private 
sector harvesting the per-diems that are paid to public servants to attend training is less 
attractive because attending training takes time, which they prefer to spend on their 
business. 
Section 11 reviews the options for combination therapies, which will have to be 
introduced in due course if malaria is to be controlled.  It concludes that there is no easy 
solution to the fact that ACT is very expensive, and even with the subsidy proposed by one 
manufacturer, will be far beyond the reach of the ordinary Tanzanian.  Whichever solution is 
chosen it must be applied to both the public and the private sector; if there is a price 
differential between the two sectors it will result in massive levels of theft. 
Section 12 considers the options for funding and implementation.  There are many 
tasks in the work plan for which NMCP will inevitably be responsible.  It was clear to the team 
that NMCP is seriously under staffed and does not have the capacity or authority at the 
moment to meet these responsibilities. Unless there is significant investment in staff and 
resources at NMCP then progress on strengthening the private sector will be very limited. 
The cost of a major investment in promoting the private sector will be substantial.  Population 
Services International (PSI) plans to spend in the order of two million dollars a year on their 
insecticide-treated net promotional activities.  A national communications package for 
antimalarials is likely to cost substantially more than this. 
Unless there is a greater commitment by the MoH to strengthening the delivery mechanisms 
for malaria control in private sector, malaria will remain a major cause of morbidity and 
mortality in the young children and pregnant women of Tanzania. 
Section 13 illustrates the work plan for the next two years and lists all the action points 
described in this report. 
The stakes are high; unless the private sector becomes the purveyor of cheap, potent 
antimalarials, taken at the right time by the right people, malaria will continue to be a major 
cause of morbidity and mortality.  This is an economic burden that Tanzania cannot afford to 
carry.  Malaria morbidity and mortality can be reduced if the focus is concentrated on the 
private sector from which most people get their drugs. 
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Introduction 
Improving prompt access to effective first-line antimalarial treatment for children under the 
age of five years, when they have fever, is one of the priority strategies identified in the 
National Malaria Mid-term Strategic Plan for Tanzania.   
Prompt access means having treatment available as near to the home as possible.  
Information and experience from countries in Sub-Saharan Africa have shown that improved 
home management of malaria (HMM) is possible but that the best way of achieving this 
improvement depends on the particular circumstances of different countries.  In Tanzania, 
where up to 40% of child deaths occur in the home, achieving prompt effective HMM is a 
particular challenge.    
The delay in seeking care for fever from health facilities averages two and a half days for 
Tanzanians and the use of private sector suppliers of drugs by rural and urban populations is 
widespread.  Antimalarials of different types and of variable quality are available in small and 
large general stores (duka la kawaida) as well as registered Part I and Part II pharmacies 
(duka la dawa).  However, adherence to the national antimalarial drug policy is patchy and 
access to information on correct dosing and recognition of early symptoms of malaria, that 
might result in improved HMM, is limited.    
In 2001, the Ministry of Health, as an interim response to increasing antimalarial drug 
resistance, recommended SP as the first line drug of choice for the treatment of 
uncomplicated malaria to replace chloroquine.   A move to an artemisinin-based combination 
therapy (ATC) is probable within the next three-four years. 
Improving appropriate treatment of malaria for children under five years of age within 24 
hours requires that quality antimalarial drugs are easy to obtain and adequately distributed 
everywhere.  People must also take the correct dose and comply fully with the treatment, 
even more challenging when considering a move to combination therapy.  Key to this is 
training and providing information to all those involved in the process from the manufacturer 
to the caregiver, including the private sector retailer or the community volunteer. 
To this end the National Malaria Control Programme (NMCP) has prioritised the need to 
identify appropriate and feasible ways in which private sector involvement in the delivery of 
antimalarials can be improved.    This includes the promotion of positive behaviour change 
among customers using drug retailers.    
The NMCP now wishes to define its strategic approach to improving private sector 
involvement and identify other private sector initiatives with which there might be 
opportunities for collaboration and from which lessons might be learned.  Preliminary 
materials for shopkeeper training, as yet untested, have already been prepared by NMCP. 
This consultancy was designed to: 
• Assist NMCP find ways to make the private sector more effective at the supply, 
distribution, storage and use of antimalarials. 
• Prepare a strategy and design a set of activities that will deliver improvements in 
retail sector provision and client use of appropriate, quality, first line antimalarial 
drugs to customers who seek treatment at retail outlets for symptoms that might be 
due to malaria. 
In Part 1 the report highlights the problems faced by the private sector, and by the 
Government authorities regulating the private sector.   In Part 2 it sets out ways in which the 
situation can be improved. 
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Part 1 Background and description of the system for the supply, distribution 
and use of antimalarials in the private sector 
1 Malaria Treatment and the Retail Sector in Tanzania 
1.1  Malaria Disease Burden 
1.1.1 Epidemiological Stratification 
Within the fragile Health Sector, malaria continues to burden the overstretched health 
services in Tanzania.   Malaria is a serious public health problem and remains the major 
childhood killer in Tanzania and ranks number one in inpatient and outpatient statistics.   
Over 80% of the country - Coastal belt, lake region, Central Plateau and Isles - the 
transmission is stable perennial or stable seasonal.   The remaining 20% of the country is 
either mountainous or fringe highlands with altitudes up to 2000 meters above sea level and 
temperatures of 200 C and is prone to malaria epidemics.  The expected pattern of 
transmission has changed in recent years with increasing reports of malaria epidemics.   
About 25% of the population live in epidemic prone areas, generally with little immunity; 
these people are susceptible to severe malaria in all age groups. 
Children under five years of age (7.1 million) constitute a high-risk group for malaria infection 
and disease.   Because of the severity of the disease and the complications of persistent 
asymptomatic infection, malaria in under fives should be promptly and appropriately 
managed using effective anti-malaria drugs.   Malaria also inflicts a huge burden due to 
anaemia, especially in pregnant women (1.69 million).1  The number of clinical malaria cases 
per year is estimated to be between 14 and 18 million with a mortality rate that ranges from 
140 to 650 per 100,000 people.   The estimated number of deaths per year due to the 
disease is 100,000-125,000 of which about 80,000 are children under the age of five years.2 
The development and spread of malaria parasites resistant to the effective, cheap and easily 
available anti-malaria drugs worsens the situation. 
1.1.2 Summary of Epidemiological Indicators 
 
Table 1   
Population at Risk in various transmission zones 
Transmission season Zone Population 
Over 6 months stable (perennial) Coastal 14,000,000 (42%)
4-6 months (stable seasonal) Central Zone 11,300,000 (33%)
1-3 months (strongly seasonal or 
epidemic) 
Fringe highlands Rift 
Valley 2,600,000   (8%)
Less than 1 month 
(Epidemic potential or no 
malaria) 
Highlands 5,800,000 (17%)
(Source: Mapping Malaria Risk in Africa – MARA) 
 
                                                 
1 Ministry of Health, National Malaria Medium Term Strategic Plan, 2002, Dar-es-Salaam, Tanzania  
2 Ministry of Health, National Malaria Control Programme, Tanzania Essential Health Project Mapping Malaria 
Risk In Africa (MARA), September 2000 
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Table 2   
Burden of malaria disease 
Estimated number of  
malaria cases per year      
Estimated number of deaths  
per year due to malaria      
Annual incidence:        
Reported annual malaria  
mortality rate, all ages     
Reported annual malaria  
mortality in 0-4 year olds                           
14-18 million 
 
100,000-125,000 (70-80,000 < 5yrs) 
400-500 per 1000 (double in < 5yrs) 
141-650 per 100,000 
300-1,600 per 100,000 
 
Source: National Malaria Control Programme, DPS, MOH 
1.2 NMCP targets and objectives for early diagnosis and treatment at community 
level 
Improved malaria case management is one of the main strategies advocated for malaria 
control in the National Malaria Medium Term Strategic Plan 2002-2007 (NMMTSP).   In the 
strategy challenges for quality anti-malaria services at the health facility and community level 
have been well articulated.   The NMCP and collaborating partners have set targets and 
operational targets for improvement of malaria case management at all levels of delivery of 
health services. 
The role of the community, and particularly the household, in health improvement, 
particularly with reference to malaria case management, is well recognized by the Ministry of 
Health, National Malaria Control Programme and its collaborating Partners.   This is 
important because effective early diagnosis and treatment at household level requires people 
and communities to have knowledge about the appropriate actions to take when a member 
of the household gets sick, especially children under the age of five years.  They also need 
access to quality treatment.  Decisions made and actions taken at the household level are 
critical for the overall achievement of the NMMTSP targets. 
1.2.1 Target on improvement of malaria at community level 
Use of appropriate treatment within 24 hours for febrile episodes in children under the age of 
five years, will be raised from 19% to 60% by the year 2007. 
1.2.2 Operational targets 
Operational targets as indicated in the NMMTSP are to ensure attainment of the above-
mentioned target on early detection and appropriate treatment of malaria in the community.    
• 60% of children under five years of age, with fever / malaria, to receive correct 
treatment according to national guidelines within 24 hours of fever onset.  
• 80% of households to receive targeted IEC messages on severe malaria and 
appropriate actions to be taken at home, including referral, according to national 
guidelines. 
• Drug stores, retail shops and kiosks to only sell high-quality first line antimalarial 
drugs and correct doses are to be dispensed. 
• The proportion of shopkeepers that are knowledgeable about antimalarial treatment 
to be raised from 15% to 60%. 
• 50% of key community owned resource persons, including traditional healers and 
village health workers, to be able to provide correct advice on early detection and 
treatment of malaria in their communities. 
In order to achieve the above targets, partnership at all levels of implementation is 
imperative.  The private sector, in view of its involvement in the delivery of antimalarial drugs, 
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is a key partner in the overall undertaking of the strategy.   It is essential for CHMTs to make 
provision for the above collaboration in the Comprehensive Council Health Plans.   It is 
expected that the private sector providers will play a key role in malaria case management 
and deliver services appropriately according to therapeutic standards as defined by the 
Ministry of Health.   Supervision is critical; the CHMTs are required to supervise service 
delivery and performance in their respective districts, including sensitisation in communities 
and promotion of judicious antimalarial drug dispensing practices by the informal sector. 
1.3 National Malaria treatment guidelines3 
High levels and degree of chloroquine resistant falciparum malaria have necessitated the 
change of treatment guidelines for malaria in Tanzania and other sub-Saharan African 
countries. 
In Tanzania chloroquine resistance in semi-immune Tanzanians was reported for the first 
time in the 1970’s.  During the 1980’s many surveys confirmed the increase and spread of 
the problem.   Conventional methods were used to test the efficacy of antimalarials, mainly in 
asymptomatic school children.  Results from such studies had some limitation for use in 
policy development, mainly due to unstandardised methods used to gather data.    
Results from the therapeutic efficacy studies carried out in four sites in 1997 and in six 
sentinel sites in 1998/1999 clearly showed high levels of chloroquine resistance, with on 
average a total treatment failure of 52% (range 28-72%).   The new WHO protocol for 
therapeutic efficacy testing was used.   Consequently, despite the fact that about 80% of 
Tanzanians live close to health facilities that provided chloroquine, statistics from such 
facilities through the Health Management Information System (HMIS) still showed that 
malaria was the first cause of outpatient attendances, admissions and death.   On the other 
hand, the cost for malaria treatment using chloroquine also increased, mainly due to re-
treatment costs.     
In view of the above and also in view of the limited practicable antimalarial options, the 
Ministry of Health changed treatment guidelines for malaria and introduced an interim 
strategy selecting sulfadoxine-pyrimethamine (SP) as the first line anti-malaria drug, 
amodiaquine as second line and quinine as third line and first choice in severe malaria.  (See 
Table 3).  Tablet formulations are preferred; syrup formulations are only recommended 
where a child is unable to take tablets. 
 
Table 3 
National Guidelines for Management of Uncomplicated Malaria at all Levels 
 Drug Formulation Duration Contraindications Notes 
1st 
line 
drug 
SP or 
SMP* 
Tablets Single-
dose 
Sulphonamide 
hypersensitivity 
Premature babies and 
children aged one week to 
two months 
Late pregnancy 
Should be 
given  
with an 
antipyretic 
2nd 
line 
drug 
Amodiaquine Tablets Three 
days 
Hypersensitivity to 
amodiaquine 
Hepatic disorders 
 
3rd 
line 
drug 
Quinine Tablets Seven 
days 
  
Source: National Guidelines for Malaria Diagnosis & Treatment, 2000 
                                                 
3 National Guidelines for Malaria Diagnosis and Treatment – Malaria Control Series no.1, 2000 
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*SMP or sulphamethoxypyrazine pyrimethamine is an alternative SP formulation with the 
same indicators and dosage as sulphadoxine pyrimethamine. 
 
SP was deployed as the first line antimalarial despite the reported average total treatment 
failure of 9.5% from the sentinel sites.  In this regard it was obvious from the outset of the 
strategy that the useful Therapeutic Efficacy of SP would be limited.  It was therefore 
deemed necessary to continuously monitor the changes in the pattern of resistance to SP 
and also to prepare for a more effective strategy - Combination Therapy - as soon as it 
becomes available.  Since the introduction of the new treatment guidelines, routine 
monitoring of SP resistance in sentinel sites shows an increasing trend up to 15%.   
1.4 Malaria Treatment Seeking Behaviour 
1.4.1 Consumer Knowledge and Beliefs 
The biomedical concept of uncomplicated malaria overlaps with the local illness concepts of 
“homa” (usually translated as fever, although it can include other symptoms), and “maleria” 
or “homa ya maleria”.  These terms generally relate to common and easily treated fevers, 
and “malaria” is frequently associated with mosquitoes4.  The biomedical concept of severe 
malaria can be linked with several local terms for the symptoms of severe disease: 
“degedege” (convulsions), “homa kali” (high fever) and “bandama” (splenomegaly).  While 
some people link these symptoms with malaria, alternative explanations are also identified, 
for example involving supernatural intervention via spirit possession or magic spells5. 
Antipyretics/painkillers and antimalarials are seen as appropriate therapies for fever or mild 
malaria, but knowledge of dosing is generally very poor.  For instance, only 20% of shoppers 
at drug stores in Dar es Salaam knew the correct dose of chloroquine for adults when it was 
still the first line drug6.  There is wide confusion over the difference between antimalarials 
and antipyretics, and between brand name and generic products.  Consumers may perceive 
two different brands of an antimalarial to be different drugs, or switch from tablets to 
injections without realising that they are different formulations of the same medicine. 
1.4.2 Treatment Sources 
Potential sources for malaria treatment include Government, mission and private facilities 
(dispensaries, health centres and hospitals), Part I pharmacies, Part II drug stores, general 
stores, and traditional healers or home remedies.    
The vast majority of suspected malaria cases treated in facilities and shops are diagnosed on 
the basis of clinical symptoms alone, most commonly just the presence of fever.  Microscopy 
is only available in a minority of facilities and a few private laboratories; in government 
facilities its use is often reserved for suspected treatment failures.  A high proportion of 
clinically diagnosed cases are not parasitaemic.  The percentage of children clinically 
 
4 Minja, H., J.  A.  Schellenberg, O.  Mukasa et al.  (2001).  Introducing insecticide-treated nets in the Kilombero 
Valley, Tanzania: the relevance of local knowledge and practice for an information, education and communication 
(IEC) campaign.  Trop Med Int Health 6(8): 614-23. 
Winch, P.  J., A.  M.  Makemba, S.  R.  Kamazima, et al.  (1994).  Seasonal variation in the perceived risk of 
malaria: implications for the promotion of insecticide-impregnated bed nets.  Social Science and Medicine 39(1): 
63-75. 
5 Hausmann Muela, S.  and J.  Muela Ribera (2000).  Illness naming and home treatment practices for malaria - 
an example from Tanzania.  Paper presented at workshop on People and Medicine in East Africa. 
Winch, P.  J., A.  M.  Makemba, S.  R.  Kamazima et al.  (1996).  "Local terminology for febrile illnesses in 
Bagamoyo District, Tanzania and its impact on the design of a community-based malaria control programme." 
Soc Sci Med 42(7): 1057-67. 
6 Massele, A.  Y., J.  Sayi, S.  E.  Nsimba et al.  (1993).  "Knowledge and management of malaria in Dar es 
Salaam, Tanzania." East African Medical Journal 70(10): 639-42 
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diagnosed with malaria who were actually parasitaemic was 62% in Kilombero District and 
38% in Kibaha District7.   
The most common source of treatment for fever is shops, which include general stores and 
pharmacies/drug stores.  In southern Tanzania 29% of recently febrile people sought care 
from a health facility, while more than 60% bought medicines from shops (Figure 1)8 30% 
bought drugs from drug stores, and 34% from general stores, showing that both types of 
retail outlet are important.   
 Figure 1   
Sources of medicines used for fever by age group  
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The frequency with which infants and children under five were taken to health facilities was 
significantly higher than that observed for older children and adults.  However, shops 
remained the most important source across all age groups.  Reported use of traditional 
healers, herbal remedies, community health workers and unregistered providers was rare for 
fever8, although use of traditional practitioners is more common for severe disease5. 
Frequent use of shops has also been demonstrated in other regions, such as Dar es Salaam 
and Same District9.   Recourse to multiple providers during a single episode is common.  
Patients often begin with self-treatment using drugs purchased through the commercial 
sector, and then only seek care from facilities if their symptoms do not resolve. 
 6
                                                 
7 Font, F., M.  Alonso Gonzalez, R.  Nathan et al.  (2001).  "Diagnostic accuracy and case management of clinical 
malaria in the primary health services of a rural area in south-eastern Tanzania."  
Trop Med Int Health 6(6): 423-8. 
Nsimba, S.  E., A.  Y.  Massele, J.  Eriksen et al.  (2002).  "Case management of malaria in under-fives at primary 
health care facilities in a Tanzanian district." Trop Med Int Health 7(3): 201-9. 
8 Kachur, S.  P., R.  Khatibu, C.  Goodman et al.  (2002).  Prevalence of malaria parasitemia and recent 
pharmaceutical medicine use by age in rural Tanzania: Implications for a multi-year evaluation of artemisinin-
containing combination therapy.  Proceedings of the Third MIM Pan-African Malaria Conference, 17-22 
November, 2002.  Arusha, Tanzania. 
9 Mnyika, K.  S., J.  Z.  J.  Killewo and T.  K.  Kabalimu (1995).  "Self-medication with antimalarial drugs in Dar es 
Salaam, Tanzania." Tropical and Geographical Medicine 47(1): 32-34. 
Alilio, M.  S., M.  L.  Kamugisha, F.  K.  Msuya et al.  (1997).  "Availability and utilization of anti-malarial drugs at 
community level in Same District North Eastern Tanzania." Malaria and Infectious Diseases in Africa 6 
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Drugs are officially provided free in most government primary health care facilities, but 
changing has been introduced in some districts.  Even where services are free patients often 
choose to pay at private facilities and shops because they are nearer to where they live.  
Common reasons for not visiting a government health facility include long journey times, rude 
and insensitive staff, limited opening hours, long waiting times, lack of diagnostic facilities 
and poor building conditions.  However, by far the most common complaint is the frequency 
of drug stock outs.  Other reasons for preferring shops are that service is much faster and 
other family members can be sent to collect the drugs.  They are also more likely to sell an 
incomplete dose of antimalarial drugs, which may be appreciated by the patient when cash is 
not available to buy a full course of treatment. 
1.4.3 Adequacy of treatment 
Having sought some kind of treatment in no way guarantees that the treatment received will 
be prompt or appropriate. 
In a household survey of seven sentinel districts in 2001 it was found that in only 42% of 
under fives was action taken within 24 hours of fever onset, and only 11.3% had received 
appropriate treatment within 24 hours10.   Inappropriate treatments were obtained from both 
health facilities and at home (Figure 2). 
 
Figure 2  
Treatment of children with febrile illness within 24 hours 
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A household survey in southern Tanzania found that only 43% of children with a history of 
fever had received antimalarials.  Children in the “least poor” quintile were twice as likely to 
have received antimalarials as those in the “most poor” quintile (Table 4), demonstrating that 
the poorest groups are least likely to obtain appropriate care. 
 
7  
                                                 
10 Abdulla, S.  et al.  (2001).  Assessments of malaria situation and control activities in Tanzania – Preliminary 
Report. 
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Table 4  
Socio-economic differences in treatment for fever 
 Socio-Economic Status Quintiles  
 Most 
poor 
Very 
poor 
Poor Less 
poor 
Least 
poor 
Average
Child with fever 
received an antimalarial 
31% 33% 49% 35% 62% 43% 
Source: Armstrong Schellenberg et al., 200311
 
Where an antimalarial is used, it is frequently taken at a sub-optimal dose, and care-takers 
are often unaware of important side-effects or the danger signs for severe disease. 
1.5 Retail Market Structure 
1.5.1 Manufacturers, Importers and Wholesalers 
There are four local manufacturers of antimalarials in Tanzania: Shelys Pharmaceuticals Ltd 
(the market leader), Interchem Pharma Ltd, Keko Pharmaceutical Industries Ltd, and 
Tanzania Pharmaceutical Industries Ltd.  A few other local manufacturers produce 
antipyretics that may be used for fever treatment, but they do not produce antimalarials. 
Registered antimalarials are imported from a wide range of countries in Africa (Kenya, 
Uganda, Senegal), Asia (India, China, Korea), the Middle East (Egypt), and Europe (France, 
Switzerland, Italy, Cyprus, Belgium, Germany, Malta). 
A total of 113 importers are registered with the Pharmacy Board, although this covers both 
medical and veterinary products.  48 of these importers are also registered as Pharmacy 
wholesalers, five or six of which are reportedly the market leaders, responsible for the largest 
shares of imported drugs.  There are 167 registered private pharmacy wholesalers, 
geographically distributed as shown in Table 5 (excludes MSD).  They are highly 
concentrated geographically with two thirds based in Dar es Salaam, and 80% in either Dar 
es Salaam, Mwanza or Arusha.  They are also geographically concentrated within Dar es 
Salaam, with most located within a few hundred yards of one another in the Kariakoo area.  
All those registered to import are based in Dar es Salaam. 
                                                 
11 Armstrong Schellenberg, J., C.  J.  Victora, A.  Mushi et al.  (2003).  "Inequities among the very poor: health 
care for children in rural southern Tanzania." Lancet 361: 561-566. 
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Table 5 
Registered wholesale and retail pharmacies in Tanzania 
Region Part I Wholesalers* Part I Retailers Part II Retailers 
 n % n % n % 
Dar es Salaam 110 66% 205 60% 1,300 23% 
Kilimanjaro 4 2% 14 4% 270 5% 
Mwanza 10 6% 22 6% 500 9% 
Arusha 13 8% 25 7% 400 7% 
Mbeya 5 3% 13 4% 226 4% 
Morogoro 5 3% 14 4% 298 5% 
Dodoma 3 2% 6 2% 255 5% 
Mtwara 1 1% 2 1% 90 2% 
Singida 2 1% 1 0.3% 185 3% 
Coast 0 0% 6 2% 85 2% 
Tanga 3 2% 9 3% 220 4% 
Iringa 1 1% 4 1% 400 7% 
Kagera 1 1% 3 1% 138 2% 
Mara 3 2% 4 1% 200 4% 
Shinyanga 3 2% 7 2% 323 6% 
Rukwa 0 0% 1 0.3% 75 1% 
Tabora 0 0% 5 1% 200 4% 
Ruvuma 1 1% 1 0.3% 150 3% 
Kigoma 2 1% 0 0% 60 1% 
Lindi 0 0% 2 1% 291 5% 
Total 167 100% 344 100% 5,666 100% 
* Excludes MSD depots 
Source: Pharmacy Board 
1.5.2 Health Care Facilities 
The government has three tiers of formal health facilities: hospitals, health centres and 
dispensaries.  They are all supplied with SP, amodiaquine and quinine.  In addition there are 
mission facilities run by a range of denominations, and a growing number of private 
commercial hospitals, dispensaries and laboratories.   
Government health facilities receive their drug supplies through the Medical Stores 
Department (MSD) that procures from a range of local and international sources.  MSD also 
sells to mission/NGO facilities, but not to commercial businesses. 
1.5.3 Retailers 
Retail outlets for drugs include Part I and Part II pharmacies and general stores (including 
kiosks and small stalls).  Part I pharmacies must be run by a registered pharmacist, and are 
allowed to sell any drug registered or licensed in Tanzania.  There are 344 registered Part I 
retail pharmacies (Table 5).  This figure includes the 167 wholesale pharmacies, which are 
all also registered to sell retail.   Sixty percent of the retail pharmacies are in Dar es Salaam, 
and the rest are distributed unevenly throughout the regions and are always located in urban 
areas.   
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However, drugs are also widely available in both urban and rural areas from general retailers 
and Part II drug shops.  The pharmacy board has records of 5,666 registered Part II stores 
(Table 5), but accepts that the total number may be considerably higher, including some 
unregistered outlets.  Part II pharmacies tend to be located on main roads or in market 
centres.  They can be run by anyone with a basic knowledge of pharmaceutical or medical 
science, such as a pharmacy assistant or a nurse.  In practice they are typically staffed by 
nurse assistants who have just one year’s training, but give a vast amount of advice to 
customers, and are treated much like a doctor by the local community.  They have only been 
allowed to sell OTC products (Part II poisons), but often illegally sell Part I drugs as well, 
such as antibiotics.  All Part II stores stock Part II antimalarials (SP and/or amodiaquine) and 
many stock some Part I antimalarials, generally quinine.  The government plans to phase out 
Part II drug stores and replace them with Accredited Drug Dispensing Outlets (ADDOs).  
(See Section 2.4). 
The general retailers range from large permanent shops to 
small temporary roadside stalls, and stock a wide range of 
household products such as soap powder and cooking oil.  
They may be in market centres or remote areas, and can 
be staffed by anyone (See Figure 3).  They generally stock 
a few common painkillers, and a minority have 
antimalarials, with just a few stocking antibiotics.  Mobile 
vendors and markets are not a common retail source of 
drugs. 
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General retailers are by far the most accessible source of 
drugs for the rural population.  For example a study of rural 
areas in southern Tanzania in 2001 found an equal number 
of primary health facilities and Part II drug stores, giving a 
population ratio of around 5,200 people per health facility 
and 5,200 people per drug store.  By contrast there were 
only 273 people per general retailer stocking drugs 
(Goodman, unpublished data). 
The distribution chains for drug shops and general stores 
are distinct.  Drug shops obtain their supplies from drug 
wholesalers or pharmacies, which in turn buy from other 
drug wholesalers or importers.  General retailers buy most supplies from general sub-
wholesalers in the nearest district/regional town, who then buy from general wholesalers or 
distributors.  At the top of the distribution chain two national general distributors (Nufaika and 
DG Traders), together with Shelys Pharmaceuticals are responsible for most of the drugs 
supplied through the general traders distribution chain12.   
Figure 3 
A child selling Part I drugs 
from a general shop 
 
2 Regulation and inspection 
2.1 New act and drug classifications – Tanzania Food, Drugs and Cosmetics Act 
The regulation of pharmaceuticals in Tanzania is in the process of change with the 
introduction of a new Tanzania Food, Drugs and Cosmetics Act, which should become law in 
2003.  The Act makes provision to deal with food, medicines, drugs, poisons, cosmetics and 
medical devices, their control and regulation.  It repeals the Pharmaceutical and Poison Act 
1978 in order to separate the functions of regulating, supervision and control of matters 
related to the pharmacy profession from others dealing in pharmaceuticals.  A new Tanzania 
Food and Drug Authority will be established to regulate all matters covered by the act.   
 
12 This was the case in the areas we visited, and we expect their dominance to be nationwide, but were not able 
to verify this during our visit. 
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The new act is also aimed at empowering the Pharmacy Board to execute its activities more 
efficiently.   It also makes provision for the Pharmacy Board to appoint inspectors down to 
community level. 
Under the new Act, drugs have been re-categorized from Part I poisons and Part II poisons 
to the following groups:  
- Controlled Drugs 
- Prescription  
- General sale drugs 
It is now being proposed that an additional category should be created: 
- Pharmacy only – Prescription and non prescription drugs only available from a 
pharmacy  
It was reported that the categorization reflects a consensus among SADC countries.   
The difference between prescription and pharmacy only groups is not clearly defined and 
may give rise to considerable confusion.  It is unclear why the additional category is deemed 
necessary. 
2.2 Drug registration 
Until the year 1997, regulations and laws governing registration of medicines in Tanzania 
was non-existent.   Mechanisms to establish/ascertain the quality of all medicines imported 
as well as manufactured within the country were lacking.  The Chief Government Chemist 
analysed drug samples collected from different outlets.   In 1997 the important regulation and 
process for drug registration started, including construction of the quality control laboratory.   
In 1999 drug registration came into force.   Since then all medicines/drugs are in theory 
required to be registered before they are made available for consumption. 
The requirements for drug registration require that::  
• the availability of the drug is in the Public interest;  
• it is safe, efficacious, and of acceptable quality;  
• the premises and manufacturing operations comply with the current Good 
Manufacturing Practice, including Internal Quality Control Assurance.   
Guidelines on Good Manufacturing Standards and Practices have been developed and 
shared with all in country manufacturers.  The head inspection Unit of the Pharmacy Board is 
required to inspect manufacturing premises at least once every year.   
A team of experts from the Pharmacy Board is required to inspect the premises overseas for 
Good Manufacturing Standards and Practices at the manufacturers’ cost before the drugs 
are registered.  A total of 67 imported antimalarial products have been registered (Table 6). 
 
Table 6  
Registered imported antimalarial drugs 
Drug Tablets/Capsules Suspension/liquid Injection Total 
SP 12 0 1 13 
SMP 1 0 0 1 
AQ 8 4 0 12 
QN 10 1 9 20 
ART 11 1 3 15 
Others 5 1 0 6 
Total 47 7 13 67 
 Source: Pharmacy Board 
Registration of locally manufactured drugs should also follow the same procedure.  The 
Pharmacy Board also organizes meetings with manufacturers that mainly focus on GMP.  At 
the time of this consultancy none of the local manufacturers had met the required GMP 
standards.  However, some locally manufactured drugs, including antimalarials, had been 
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given temporary approval for distribution pending registration, and it is expected that 
registration will be possible later this year when standards are met.  During this interim phase 
it was reported that the Pharmacy Board is carrying out close monitoring of the 
manufacturers and their products.   
Despite these arrangements that are intended to ensure availability of quality drugs in the 
country, the study team identified plenty of unregistered drugs of unknown quality in the 
market.   
2.3 Part II pharmacies Registration 
Part II pharmacies have to be registered through the Regional board and then have to re-
register once a year.  The board issues its permits annually after it is satisfied that the facility 
meets requirements.  Thus if a new Part II pharmacy opens up it may function informally for a 
period without a permit.  The team found unregistered Part II pharmacies.  It is not clear if the 
unregistered Part II pharmacies are just ones that are in the process of registering or are in 
fact ones that do not intend to register. 
2.4 Inspection 
The Inspection Unit within the Pharmacy Board has the mandate to inspect premises where 
drugs are sold.  The Regional Pharmacist and Council Health Management Teams, 
particularly the District Pharmacist, are all responsible for inspection.   
2.4.1 Manufacturers 
A team of experts from the Pharmacy Board is required to visit and inspect premises that 
manufacture drugs both nationally and internationally.   
2.4.2 Wholesalers  
It is the responsibility of the Inspection Unit at the Pharmacy Board or the Regional 
Pharmacist to routinely carry out inspections of wholesalers.  The study found that this 
important activity is not well done. 
2.4.3 Part I and Part II Pharmacies  
The regional Pharmacist or CHMTs are required to routinely inspect Part I and Part II 
facilities.  The implementation of this activity was found to be sporadic in most of the areas 
visited due to lack of transport.   
2.4.4 General stores  
General stores sell a variety of essential commodities, for example, sugar, salt and soap.   A 
variety of drugs ranging from analgesics, antimalarials - mainly amodiaquine (Amodar) - 
antibiotics - Shetrim syrup (Cotrimoxazole) - to sedative hypnotics like Diazepam were also 
found in some shops.  Anybody in the family, however unskilled he/she is, can provide 
service in such shops.  (See Figure 3.) 
Health Assistants carry out supervision for General stores, mainly focusing on hygiene 
issues and tax revenue collection.  Discussions with a Health Assistant revealed that they 
visit every general store at least once per annum using whatever means of transport is 
available, for example bicycle.  Transport was found to be the main obstacle for efficient 
undertaking of the supervisory activity.  Health Assistants lack knowledge about drugs and 
they are not allowed to confiscate illegally sold drugs.   
2.5 Planned phasing in of Accredited Drug Dispensing Outlets (ADDO)13 
The 1978 Pharmaceutical and Poisons Act allowed Part II pharmacies (Duka la Dawa Baridi) 
to sell non-prescription drugs.   
 
13 The Pharmaceuticals and Poisons (Standards for Accredited Drugs Dispensing Outlets –ADDO) Regulations, 
2002   
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However, from the data available the major issues related to the quality and cost of care 
provided by duka la dawas are: 
• Insufficient number of qualified staff 
• No assurance of drug quality 
• High drug prices charged to patients 
• Insufficient variety of drugs legally available to meet consumer needs. 
Each of these problems are exacerbated by: 
• Inadequate enforcement of regulations 
• Difficulty in finding reliable, and legal, sources of drugs and supplies. 
The ADDO programme is designed to address each of these problems. 
Management Sciences for Health (MSH) and the MOH collaborated in conducting an 
assessment of the pharmaceutical sector in Tanzania in 2001.  On the basis of that 
assessment a proposal was developed to improve access to essential drugs and health 
supplies in Tanzania through developing public-private partnerships.  The objectives of the 
proposal were to: 
• Improve the availability of cost-effective essential drugs and health supplies in public 
and mission hospitals; 
• Promote competitive pricing for selected essential drugs in the private sector in rural 
Tanzania; 
• Improve the quality of pharmaceutical services in the private sector in rural Tanzania; 
• Improve the quality of selected imported and locally manufactured essential drugs in 
the Tanzanian market. 
The MOH and MSH agreed to accomplish these objectives through: 
• Designing, implementing and monitoring a network of Accredited Drug Dispensing 
Outlets (ADDOs), licensed and regulated by the Drug Regulatory Authority, with 
monitoring and enforcement carried out in collaboration with local government and 
community health structures; 
• Approving alternative suppliers to serve hospitals supported by public finances; 
• Implementing a system of screening, monitoring, and reporting on the quality of 
selected essential drugs under the Authority of the Drug Regulatory Authority. 
Regarding each of the objectives listed above: 
The official launch of the ADDO programme as signified by the opening of the first ADDOs is 
planned for August 2003. 
A confidential discussion document prepared by MSH that describes an alternative supplier 
system for hospitals supported by the public sector is under study by the MOH.  In addition 
MSH has developed, in conjunction with the Evangelical Church in Tanzania (ELCT), a pilot 
alternative supplier programme for church hospitals located in the Northern Zone of 
Tanzania.  This programme is scheduled to be launched in November 2003. 
A comprehensive drug quality programme for assuring product quality, including a range of 
components, including the review and analysis of documentation, visual inspection, product 
testing using both qualitative and quantitative methods, monitoring of products and 
manufacturers and effective enforcement of regulations, was launched by the Tanzania Food 
and Drug Authority in October 2002.   
A minimum list of prescription essential drugs consistent with the yellow, Indent system and 
life saving potentials will be allowed at the ADDO.  A registered wholesaler will distribute 
registered drugs to ADDOs.  Inspection and monitoring will be the responsibility of the Ward 
Health Committees, District Technical Advisory Committee, Regional Technical Advisory 
Committee and the Pharmacy Board.     
A marketing approach will be used for improvement of appropriate practices through 
communication, training and support.    
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The ADDO scheme is ambitious and its chance of success hinges on the adequacy of 
inspection at the ward level.  Given the inability to inspect the existing Part II pharmacies it 
seems unlikely that adequate inspection will be achieved unless a major investment is made 
to provide a large number of inspectors with enough transport to enable regular inspection to 
occur. 
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Part 2 Key Concerns and Action Points 
Thus far this report has described the system used for the supply of antimalarials through the 
private sector.  The rest of the report sets out the team’s main concerns and identifies the 
actions that need to be taken if the systems are to improve. 
3 Ensuring Product Quality 
The impact of all efforts to ensure appropriate use of antimalarials will be severely 
compromised if the drugs themselves are not of good quality.   
Unfortunately there is substantial recent evidence of poor quality antimalarials in Tanzania.  
In 2001 the Pharmacy Board tested 16 different brands of SP/SMP on sale in Dar es 
Salaam, and found only six were of good quality.  A local brand that failed this test was 
purchased by MSD for distribution in drug kits for government facilities, and had to be 
recalled in late 2001 when it was discovered that certain batches were of poor quality.  Risha 
et al.(2002) examined the quality of chloroquine and SP from Dar es Salaam wholesalers 
collected between 1998 and 200014.  All samples passed the pharmacopoeia requirements 
for drug content, but two of the four SP products failed the dissolution test.  Although all 
chloroquine samples passed initial dissolution, two out of seven failed to meet dissolution 
tolerance limits after being subjected to an accelerated stability test under simulated tropical 
conditions (75% RH/40˚C) for six months.   
These incidents relate to substandard products which have been poorly manufactured.  
Counterfeit antimalarials deliberately manufactured without the appropriate active ingredient 
also circulate widely in the international market, with many occurrences reported in South 
East Asia15.  While the prevalence of counterfeits on the Tanzanian market to date has been 
rare, the increasing use of more expensive antimalarials, such as artemisinin derivatives, 
may increase incentives for producing or importing counterfeit products in future. 
Quality assurance encompasses ensuring both that the drugs entering the market are of high 
quality, and that they are still of high quality when they reach the consumer.  The Pharmacy 
Board is in the process of implementing a number of important strategies to improve quality 
assurance: 
• Local manufacturers and GMP.  As mentioned in Section 2.2 the Pharmacy Board 
is working with local manufacturers to support the introduction of Good Manufacturing 
Practice (GMP) and internal quality assurance in all Tanzanian pharmaceutical 
factories.  This process aims to balance the needs to both enforce more stringent 
quality standards and promote local industry.  It has involved the development of 
GMP guidelines, repeated consultation and inspection of local plants, with a final 
inspection planned in the second quarter of 2003.  Factories passing this inspection 
will acquire GMP status and will be able to register their products16.  Any failing the 
inspection will have to cease production.   
• Drug quality testing at ports of entry.   In collaboration with MSH/SEAM, the 
Pharmacy Board has established quality testing facilities at major ports of entry: 
Namanga and Sirari on the Kenyan border, Dar es Salaam harbour and Dar es 
Salaam airport (temporarily located at headquarters).  The Pharmacy board hopes in 
future to restrict the importation of drugs to ports of entry with testing capacity.  
Testing began in late 2002.  The sites use minilab testing kits based on Thin Layer 
Chromatography (TLC), but plan to move to stand alone TLC testing systems in the 
 
14 Risha, P.  G., D.  Shewiyo, A.  Msami et al.  (2002).  "In vitro evaluation of the quality of essential drugs on the 
Tanzanian market." Tropical Medicine & International Health 7(8): 701-707. 
15 Newton, P.  N., N.  J.  White, J.  A.  Rozendaal and M.  D.  Green (2002).  "Murder by fake drugs." BMJ 
324(7341): 800-1. 
16 To date no locally manufactured antimalarials have been registered because production does not meet GMP 
standards.  However, a number of products have been given a temporary licence to distribute, pending GMP 
inspection.   
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future.  Any products failing the test will be sent to the National Drug Quality Control 
Laboratory (NDQCL) for confirmatory testing within a 14 day period.  No failures had 
been identified in the first four months of implementation.  The minilabs have the 
capacity to test the following antimalarials: artesunate tablets, quinine bisulphate 
tablets, quinine sulphate tablets and sulphadoxine/ pyrimethamine (SP) tablets.  This 
list will be extended to include amodiaquine, sulphamethoxypyrazine/ pyrimethamine 
(SMP), and other artemisinin-based drugs once appropriate methods have been 
developed.   
• Post Marketing Surveillance.  Minilab testing facilities have also been introduced at 
the regional level (Dodoma, Mtwara and Mbeya), to undertake market surveillance 
through routine sampling and quality testing of products from MSD, wholesalers, Part 
I and Part II pharmacies.   
Important strides have been taken in improving quality assurance, which will be of great 
benefit to antimalarial consumers.  However, some important gaps remain in both policy 
design and implementation. 
3.1 Ensuring Quality of Registered Antimalarials at Factory Gate/ Point of Entry 
Key Concerns 
Lack of quality control for locally manufactured antimalarials.  All imported antimalarials 
must be tested at port of entry.  Such routine quality testing is not required for locally 
manufactured drugs, which only require Pharmacy Board testing prior to registration.  It is 
argued that the systems of internal quality assurance currently being established by local 
manufacturers will be sufficient for routine monitoring.  This is inappropriate and inadequate.  
The internal quality assurance systems are new and there are likely to be teething problems.  
Moreover, quality testing is required of all imported brands, even though they must also 
come from factories with GMP standards.  Finally, as a general rule, in any context it is 
extremely unwise to rely entirely on private market self-regulation. 
Lack of quality control for several key antimalarials.  The quality control of imports 
currently only covers artesunate, quinine and SP tablets.  Although there are plans to 
introduce amodiaquine, SMP and other artemisinin derivates in the future, their exclusion 
represents a major gap at present, as does the absence of any syrup or injectable 
formulations from the tested list.   
Action Points 
Include locally manufactured products in routine quality control.  As well as testing 
imported antimalarials, government capacity should be established to test all batches of 
locally manufactured antimalarials. 
Expand the range of products tested at minilabs.  The inclusion of amodiaquine and SMP 
tablets in routine quality control checks at ports of entry must be prioritised.  The potential to 
add syrup and injectable antimalarial formulations to the products tested in mini-labs should 
also be investigated.   
Antimalarials not tested by minilabs should be tested routinely at NDQCL.  While 
waiting for appropriate methods to be developed for other antimalarials, these products 
should not go completely unchecked.  Capacity exists at the NDQCL to test all of these 
drugs.  While it may not be possible to test every batch produced or entering the country, 
batches should be sampled at the factory gate or port of entry, and the samples transferred 
to the NDQCL on a routine basis.  In Dar es Salaam in particular this should be relatively 
easy to implement, as the port of entry testing for Dar es Salaam International Airport is 
currently done at the NDQCL. 
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3.2 Preventing Distribution of Unregistered Antimalarials 
Key Concerns 
Widespread availability of unregistered 
antimalarials   
As described in Section 2.2 a drug registration 
system was established in Tanzania in the late 
1990s.  In theory only registered antimalarials 
should be imported and distributed in Tanzania.  
In practice, unregistered drugs are widely 
available.  A recent SEAM survey found that 46% 
of drugs circulating in the market were not 
registered.  This was clearly still common during 
our field work in Feb/March 2003 when in visits to 
retail outlets in just a few regions we saw over a 
dozen unregistered antimalarials, examples being 
chloroquine products (registration withdrawn), SP 
syrups (formulation not registered), and a product 
being sold as an SMP which contained the wrong 
sulphonamide component17.  Unregistered products  
had been imported from a range of countries, including  
Kenya, Uganda and India.  (See Figure 4) 
Figure 4 
Some of the unregistered drugs 
collected by the team 
Figure 5 
Registration 
Number
 
Lack of knowledge about registered drugs.  A key cause of this 
problem is that very few people know which products are 
registered.  The Pharmacy Board is trying to address this by 
requiring that the registration number be printed on outer 
packaging (See Figure 5).  They are also providing port of entry 
inspectors with up-to-date registration information.  However, this 
is clearly still inadequate and will not address those products that 
are imported through unofficial channels. 
 
 
 
 
Action Points  
Print registration number on inner and outer packaging.  As drugs in blister packs often 
become separated from their outer packaging/box before use, it would be prudent to require 
that the registration number be printed on both the inner and outer packaging of the product.   
Checklist of registered products.  A clear checklist of all currently registered general sale 
products should be prepared by the Pharmacy Board.  The list should be clearly presented, 
and ordered alphabetically by brand name, so that any product found in a Part II Drug Shop 
or general store can quickly be checked against the list.  The list should be distributed to all 
drug inspectors, wholesalers, and retailers.  It would be particularly beneficial for health 
assistants, who are the only inspectors of general stores, but do not have expertise in 
pharmaceuticals and are often unable to judge whether the drugs they encounter are 
permitted.  It could also be produced in the form of a poster for display in Part II outlets to 
enable consumers to check the registration of products before they buy.  The list must be 
reprinted and redistributed regularly to ensure that it is up-to-date. 
                                                 
17 A drug called Alpakelfin from India that contained sulphamethoxazole instead of sulphamethoxypyrazine.  
(See Figure 4). 
17  
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Education campaign on registration.  The message that you cannot be sure of the quality 
of any unregistered product must be clearly conveyed to retailers and consumers.  This 
should form an important component of the communication package (see section 8), in 
tandem with information on how to find out which products are registered.   
3.3 Ensuring the Maintenance of Drug Quality during Distribution and Sale 
Key Concerns 
Poor stock management by wholesalers.  
There is considerable variation in the quality 
of stock management by drugs wholesalers.  
While some have well organised stores, run 
on a strict first in first out (FIFO) basis, 
others are verging on the chaotic, with 
drugs from different therapeutic groups 
jumbled together, not sorted by expiry date, 
and only intermittent use of air conditioners.  
The failure to follow a FIFO regime means 
that products sit for long periods at the 
wholesaler level.  For example we found a 
Tanzanian SP product in a Dar es Salaam 
wholesaler already 14 months beyond its 
date of manufacture.  (See Figure 6).  While 
products beyond their expiry date are very rarely 
found in retailers, it would be preferable for drugs t
reach the consumer as soon as possible, esp
in view of the likelihood that they will be exposed to
high temperatures and high humidity at some stage 
during the distribution chain.   
o 
ecially 
 
Poor packaging for transportation of drugs 
from wholesaler to retailer.  Again there is 
considerable variation in practices, with some 
wholesalers packing drugs in a well ordered 
manner in sealed boxes, and others allowing 
retailers to pack products as they pleased, often 
carrying them away in loose carrier bags.   
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Widespread use of tubs/tins in shops:  
According to the regulations all drugs in Part II 
outlets and general stores should be sold in unit 
dose packs, meaning they should be pre-packaged 
by the manufacturers in blisters, foil or paper.  In 
practice drugs are often sold from tubs/tins containing 
500 or 1000 tablets, and dispensed in home-made 
paper envelopes or even just a twist of newspaper.  
(See Figure 7).  This is a dangerous practice for 
several reasons.  Many shops do not have sufficient 
turnover to use the contents quickly, so tablets are 
liable to sit on the shelf for extended periods in tins that 
are not air-tight.  Their quality may also be damaged 
because the drugs are unprotected and are at risk of 
being spoilt or contaminated.  There is also concern 
about the quality of the dosing instructions provided 
with drugs sold from tins.  (See Figure 8).  Many tins 
intended for facility use do not have any instructions, 
saying merely “Dosage as directed by your physician”.  
Even if the instructions are written on the tin, they are not taken away by the consumer, who 
either gets no instructions or a hastily scribbled note that they are unlikely to understand.  
 
Figure 7 
Selling SP from a tub 
 
Figure 8 
Poor Dosing Instructions 
 
Figure 6 
Poor Stock Management by Wholesaler 
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Finally, it is easy and common for tablets to be decanted from one tin to another, either to 
hide their true origin (e.g. because they have passed their expiry date or are stolen from 
health facilities) or just for convenience (e.g.  an owner who splits the contents of one tin 
between the three drug stores he owns).  This makes it impossible for consumers or 
inspectors to verify the true identity of a product, or whether it is in date. 
 
Action Points  
Working with wholesalers to improve their practices.  The Pharmacy Board is working 
with local manufacturers to assist them in implementing internal quality assurance.  A similar 
relationship should be established with the main drugs wholesalers, perhaps through one of 
the professional associations (Pharmaceutical Society of Tanzania (PST) or Tanzanian 
Association of Pharmaceutical Industries (TAPI)).  The interaction should focus on the 
importance of good stock management and storage, packing for distribution, knowledge 
about regulations and drug registration in particular.  As with the manufacturers, a timetable 
for improved practice should be established, with strict sanctions if these targets are not met.   
Eliminating tins of antimalarials from Part II drug shops and general stores.  The 
regulations banning the sale of drugs from tins should be strictly enforced for antimalarials.  
The issue should be highlighted with retail drugs inspectors, and wholesalers and retailers 
should be alerted to the intended clampdown and its rationale.  The Pharmacy Board could 
also work with local manufacturers to encourage them to produce all their antimalarial tablets 
in blister packs.  A concern is that this may increase the cost of antimalarials to consumers, 
although tablets in tins and blisters are frequently sold for the same price in retail outlets.   
3.4 Post Marketing Surveillance 
Key Concerns 
Accuracy of tests performed at regional minilabs.  At the regional minilab visited during 
fieldwork, the technician clearly failed both to follow the testing instructions correctly and to 
interpret the results accurately.  It was not possible to assess how representative this was, 
but the standard of tests performed at these sites it likely to be a concern, because 
technicians are inexperienced, they do each test relatively infrequently, and lack appropriate 
technical supervision.   
How can information from regional minilabs be used?  Even if tests are performed well 
at regional minilabs, it is not clear how knowledge of the quality of a sample from one 
particular outlet will add value to a national quality assurance system.  If the problem arose 
during manufacture it should be picked up by minilabs at the factory gate or port of entry.  If it 
arose due to poor distribution or storage, it will not be possible to prove where the problem 
arose.  Moreover, by the time a retail sample is taken, tested and verified at NDQCL, a high 
proportion of the drugs in question will probably already have been dispensed to the 
population.   
 
Action Points  
Abandon post marketing surveillance role for minilabs.  We recommend that random 
routine testing of drugs in retail outlets in the regions be abandoned.  The activities of 
minilabs should be focused on checking the quality of drugs at the top of the distribution 
chain (factory gate or point of entry).  The energy of inspectors at national and regional level 
should be invested in ensuring that the distribution chain meets the operational standards for 
appropriate transportation and storage.  Such a quality assurance system should then 
guarantee that only good quality drugs enter the distribution chain, and that their quality is 
maintained until the point of retail sale. 
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4 Appropriate and understandable labelling and instructions 
The quality of labelling and the clarity of instructions is varied; there are five aspects that 
cause concern. 
Key Concerns 
Labelling on blister packs: Labelling is often quite inadequate with writing so small that it is 
impossible to read.  Manufacturers print their brand name larger than the generic name and 
dosing information may be incomplete, e.g. information for paediatric doses not provided.  
(See Figure 9).  As a result, consumers believe that various brands of the same product are 
different products.  The products are not easily recognizable, resulting in confusion even 
among retailers.  Blisters are packed as adult doses and some blisters are sold without an 
outer packing.  Consequently if a paediatric dose is sold the adult dose is cropped and the 
dosing information is lost.  Even if the blister comes in a box with clear dosing instruction on 
the back, there is only one copy so when a dose that is less than an adult dose is sold the 
dosing information is lost or the remaining tablets lose their outer box.   
Figure 9 
Examples of labelling 
   Inadequate labelling                                 Good labelling on 
   on a blister pack                                       a blister’s outer box 
 
Lack of measuring devices. Most of the packs for syrups and mixtures found in the outlets 
visited specified a dose based on a standard 5ml teaspoon but did not include a measuring 
device in the packet.  Mothers whose children require 
treatment with antimalarial syrups therefore use 
domestic teaspoons, which come in different sizes and 
are not of standard measure (5ml).  This results in 
either over doses or under doses depending on the 
sizes of the teaspoons used.  A minority of 
manufacturers do include a measuring cap (See Figure 
10) and when one manufacturer was asked if he could 
include a spoon or cap with every syrup he confirmed 
that there would be no significant cost implications. 
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Language.  The regulations specify that instructions 
can be in English and/or Swahili.  Most antimalarial 
manufacturers only include English, which is a major 
problem for OTC drugs as the majority of Tanzanians 
are not fluent in English 
Use and Labelling of tubs/tins.  Drugs supplied in 
tubs or tins do not usually include dosing information.  
In addition, the team found on a number of occasions 
that tubs had been recycled; at best the batch number 
and expiry date did not relate to the present contents and at worst the description on the 
outside did not match the contents.   
Figure 10 
Syrup with a measuring cap 
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Dosing instructions.  There is inconsistency in the dosing instructions provided for two 
general sale antimalarials.  Confusion has arisen regarding to the manufacturers’ dosing 
instructions given on the labels of brands of sulphamethoxypyrazin/pyrimethamine (SMP).  
Some overseas and local manufacturers recommend a single dose of two tablets for all 
adults while others recommend three tablets.  Others recommend two tablets for adults 
below 70kg in weight and three tablets for those above 70kg in weight.  The National Malaria 
Control Programme recommends three tablets as a single dose for adults and this is clearly 
indicated in National Guidelines for Malaria Diagnosis & Treatment.  The recommended 
dosage for amodiaquine is not consistent.  Table 7 shows the three options found by the 
team.  Option 2 is the one recommended by the NMCP in the National Guidelines for Malaria 
Diagnosis & Treatment.  Option one and three are those recommended by different 
manufacturers. 
Table 7 
Different dosing regimens for Amodiaquine – number tablets for adult dose 
 1st day 2nd day 3rd day 
Option 1 3 3 3 
Option 2 3 3 2 
Option 3 3 2 2 
 
 
Action Points  
Ensure that the products sold in Part II shops and general stores are sold in their 
original packs as closed by the manufacturers as required by the PB guidelines for Part II 
poisons to avoid use of wrong labels for the right drug. 
It would be relatively straightforward to address these issues through the leverage the 
Pharmacy Board has through its registration process, for example by stating that in 2004, 
only amodiaquine, SMP and SP products conforming with the following regulations on 
improved labelling and packaging will be registered. 
Inclusion of dosing information in Kiswahili as a requirement for registration, at least 
for antimalarials.  This will enable all Tanzanians to follow dosage instructions easily, 
communicate without message distortion, be motivated and encouraged to read the 
instructions on the label. 
All dosing information to conform to National Malaria Treatment Guidelines.  This will 
eliminate confusion over SMP and amodiaquine dosage regimens.   
Dosing information must be supplied for all age groups. 
Manufacturers should include measuring devices in all syrups/mixture packages. 
Generic names must be in large clear letters (larger than brand name). 
Because packs often need to be split for paediatric doses, enough extra cards repeating 
the instructions printed on the back of the packet should be inserted into the box so 
that one card could be taken away with each tablet . 
Improved labelling and packaging instructions must be a pre-requirement for re-
registration. 
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5 Increasing the Availability of General Sales Antimalarials 
5.1 The Importance of General Stores for Rural Households 
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If households living in remote rural areas are to 
have easy access to outlets selling a
these drugs must be widely available throu
general stores.   
Although Tanzania has a relatively good n
of primary health care facilities, much of the 
population remains more than 30 minutes trave
time away.  Part II drug stores provide an 
important alternative source of drugs, but are 
generally located in market centres or on main 
roads, often close to health facilities.  Demand 
for drugs is rarely high enough to encourage the 
establishment of drug stores in remote areas.  
By contrast, the network of general shops and 
kiosks has the potential to reach even the most 
remote populations, providing an effective 
distribution chain for a wide range of consumer 
goods, with long opening hours and no waiting 
time.  Figure 11 shows a shamba shop located far from permanent settlement yet selling 
drugs, including antimalarials (although out of stock when we visited). 
Figure 11 
Shamba shop selling drugs 
5.2 Drugs Stocked by General Stores 
Most general shops and kiosks stock a limited range of general sale antipyretic analgesics 
such as paracetamol, aspirin, and various combinations of the two, such as Hedex™ and 
Action™.  Only a minority stock antimalarials, and this share has fallen since the change in 
national first line policy.  In rural areas of southern Tanzania 29% of general stores stocking 
some drugs had antimalarials in 2000, which had fallen on 24% in 2001 (Goodman, 
unpublished data).  Field visits in 2003 indicated that this share has continued to fall.  Where 
general shops do stock an antimalarial, this is now most likely to be amodiaquine; SP is very 
rarely available in these outlets.  The sale of antimalarials is more likely in general stores 
located far from Part II drug stores.  A few remote general stores also stocked some 
prescription drugs, such as quinine and antibiotics, but this was unusual. 
5.3 Regulations on Drugs Allowed in General Stores 
The regulation of pharmaceuticals has been revised under the Tanzania Food, Drugs and 
Cosmetics Act, 2003, which should play an important part in clarifying the situation for 
general stores.  Pre-2003 the situation was very confused.  Drugs were categorised as Part I 
poisons (prescription only) or Part II poisons (over-the-counter), with Part II drug stores only 
allowed to stock Part II products.  However, general stores were not covered under the 1978 
Pharmaceuticals and Poisons Act, or perceived to be within the Pharmacy Board’s regulatory 
remit.  It appeared that officially general stores were not allowed to stock any drugs, but in 
practice they were permitted to sell some Part II poisons, such as common painkillers.  
Chloroquine was generally permitted until it was removed as first line antimalarial and 
effectively banned in 2001.  Subsequently it was very unclear whether general stores were 
allowed to stock the new first line antimalarial, SP. 
The 2003 Act has replaced the Part I/Part II classification with three groups: “controlled 
drugs”, “prescription drugs” and “general sale drugs”18.  It states “any general sale drug may 
be sold either by way of retail or wholesale in an open shop”.  SP and amodiaquine will be 
designated as general sale drugs, and will therefore be permitted in general stores. 
 
18 With a fourth category of “Pharmacy only drugs” being considered. 
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Key Concerns 
Poor access to first and second line antimalarials. The patchy availability of antimalarials 
in general stores, and particularly the limited availability of SP, severely restricts access to 
first and second line antimalarials for remote rural populations by increasing the travel time 
and costs associated with obtaining appropriate medication.   
Limited price competition. The limited number of retail antimalarial stockists restricts the 
downward pressure on antimalarial prices that would result from more widespread 
competition. 
5.4 The Causes of Poor Antimalarial Availability in General Stores 
The key factor limiting the stocking of antimalarials in general stores is that they are not 
available at the general sub-wholesalers where retailers purchase the majority of their 
supplies.  Many retailers told us they would like to stock antimalarials but did not know how 
to get hold of them.  This in turn reflects the lack of availability all the way up the general 
trader distribution chain.  There are several possible reasons for this situation:  
• There was considerable confusion among retailers and wholesalers about 
antimalarial regulation.  Many owners and sellers believe they are not allowed to 
stock SP and/or amodiaquine, or are unclear about the regulations, and fearful of 
incurring regulatory sanctions. 
• The capital cost of buying bulk packs of antimalarials was too high for smaller 
retailers, who were concerned that they would not be fast moving. 
• There is a common perception among retailers and consumers that the appropriate 
place to buy antimalarials is a Part I or Part II pharmacy, and that general stores do 
not supply these kinds of products.  Chloroquine had become an exception to this 
rule, perhaps because it was such a familiar product, but this perception has not been 
transferred to SP since the change in policy.   
In view of the lack of antimalarials in general wholesale shops, mobile distributors are a 
common source for general retailers.  We heard about a range of distributors, including 
registered van salesmen from local manufacturers or major importers, independent van 
salesmen travelling from Kenya, and individuals travelling by bicycle with a large bag or 
suitcase full of drugs.  Mobile distributors have the advantages of reducing travel costs for 
retailers, and providing a direct channel for manufacturers or importers to communicate with 
retailers and supply them with promotional material.  However they are extremely difficult for 
local or national authorities to monitor and control, and therefore represent a relatively easy 
distribution channel for unregistered drugs and the sale of prescription medicines to non-
Pharmacy outlets.  It would therefore be preferable if the main source of antimalarials for 
general stores were the static general sub-wholesalers where they already purchase most of 
their painkillers and non-drug products. 
 
Action Points  
Several steps must be taken to encourage the sale of antimalarials in general stores.  This 
will definitely include SP and careful consideration is needed for the reasons outlined in Box 
1 on whether these strategies should also encompass amodiaquine. 
Effective communication of drug regulations.  It is essential that all those involved in the 
retail drugs market are clear about which types of drug can be stocked in general stores, and 
which brands are registered (or licensed for distribution) in Tanzania.  This information 
should form a key part of the communication package for consumers, retailers, wholesalers, 
national distributors and local manufacturers (see section 8.1).  Particular emphasis should 
be placed on reassuring general retailers in remote areas with few or no drug stores, and 
encouraging them to stock recommended antimalarials. 
Encouraging national distributors to stock and promote SP and deciding whether to 
encourage them to stock and promote amodiaquine.  Individual retailers and sub-
wholesalers have very little control over the products they stock because the product range is 
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effectively determined by a small number of national distributors.  Discussions should be held 
with the national distributors to clarify the regulations and encourage them to include SP.  
The MOH will need to make a decision on whether to encourage them to include 
amodiaquine (see Box 1).  Distributors should be encouraged to stock only products 
appropriate for general retailers (i.e. blister packed with clear labelling and dosing 
instructions in Swahili).  An alternative (or complementary) approach would be to work 
through a parallel distribution network, which bypasses the national distributors, as PSI does 
by delivering products such as Ngao (insecticide re-treatment kit for mosquito nets) and 
Salama condoms direct to large wholesalers.  This, however, raises problems of 
sustainability. 
Encouraging manufacturers to produce smaller bulk packs.  Blister packed SP and 
amodiaquine are generally sold wholesale in boxes of 75 tablets (25 packs of 3 tablets) for 
Tsh 1700-3000 for amodiaquine, and Tsh 3500-4500 for SP.  The introduction of smaller bulk 
packs (e.g. 30 tablets per pack) should encourage more small retailers with limited capital to 
stock antimalarials. 
Link with communication package for consumers.  These interventions on the supply 
side will be complemented by the communication package for consumers (see section 8) to 
encourage early treatment of febrile illness with appropriate antimalarials and to raise 
awareness about local sources of antimalarials.   
6 Controlling availability of restricted products 
The Pharmaceuticals and Poisons Act and Pharmaceuticals and Poisons Regulations have 
governed the provision of pharmaceutical services in Tanzania. 
This law provides control of the pharmacy profession and matters relating to dealings in 
pharmaceuticals in Tanzania under the Pharmacy Board. 
The law recognizes two categories of drugs; “prescription drugs”, legally described as Part I 
poisons, and “non- prescription drugs”, legally described as Part II poisons. 
Currently, there is a transition to change to the new act called the Tanzania Food, Drugs and 
Cosmetics Act under the administration of Tanzania Food and Drugs Authority.  The new act 
will soon be applied to introduce the Accredited Drug Dispensing Outlets (ADDOs) to replace 
the current Part II pharmacies on a pilot basis.  The ADDOs will be allowed to stock a limited 
number of approved antibiotics and other Part I drugs including injectables. 
Areas of Concern 
There is already widespread availability of restricted Part I drugs including antibiotics and 
Part I antimalarials in Part II outlets, which is against the current regulations.  Government 
healthcare workers in various dispensaries and clinics often send patients to buy Part I drugs 
such as antibiotics, injectable presentations of various products and anti-diabetics from Part 
II outlets. 
Unregistered products such as various brands of sulphadoxine/pyrimethamine, quinine, 
amodiaquine syrups and tablets and artemesinin derivatives are also available in Part II 
stores.  
During the fieldwork, a substantial quantity of Part I drugs such as antibiotics and, to a small 
extent, some sedative hypnotics like diazepam were also found in general stores.  A good 
number of those drugs were available in loose tablets packed in tins. 
The availability of the restricted products in Part II and general outlets were attributed to: 
• High levels of demand by the community.   
• Referral by health workers to the private sector when the public sector is out of stock.   
• Inadequate information about regulations at all levels (confusion about which drugs 
are Part II drugs among inspectors and retailers). 
• Lack of drug inspection in general stores.  Such stores are not normally inspected by 
Council Health Management Teams (CHMTs) but by ward level Health Assistants 
who inspect all commercial outlets for environmental health reasons.  They know little  
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Box 1:  Which Antimalarials should be focused on in Retail Outlets? 
An important choice must be made about which drugs the intervention package should focus 
on in retail outlets.  SP tablets and amodiaquine tablets and syrup will be designated as 
general sale drugs, and therefore legally available for sale by all retailers.  According to the 
National Treatment Guidelines amodiaquine should only be used as a second line 
antimalarial, or where treatment with SP is contraindicated.  However, in reality it is widely 
used as the first line drug for febrile illness treated with shop-bought drugs, and is often the 
only antimalarial available in general stores.  This reflects both the demand and supply 
conditions in the market.  On the supply side, amodiaquine is much more widely available in 
the general trading distribution chain, but SP is rarely seen and often believed to be 
prohibited.  On the demand side, many consumers have been affected by the adverse 
publicity surrounding SP, in particular media stories about the effects of Steven Johnson 
Syndrome and reports about poor drug quality of locally manufactured brands.   
It is clear that the intervention package must be proactive in promoting SP tablets through 
general stores.  A choice must be made about whether to promote the correct use of 
amodiaquine tablets through general stores, or to try and discourage their use as a first line.  
Discouraging amodiaquine use will be very difficult.  As a general sale drug, it is likely to 
continue to be widely available and widely used.  Without appropriate promotion, it will 
continue to be poorly used.  Moreover, by trying to work against the flow of demand, the 
overall communication strategy will be more challenging.  It could be argued that 
amodiaquine should not be promoted in retail outlets because of the small risk of serious 
side-effects, but it is possible that this risk will increase if amodiaquine is widely available but 
inappropriately used.  Some would therefore argue for the joint promotion of appropriate use 
of both SP and amodiaquine in general stores19.  On the other hand increasing resistance to 
amodiaquine, which may develop more quickly since withdrawal of chloroquine and greater 
use of amodiaquine, may lead to more frequent dosing of children, which could increase the 
frequency of severe adverse reactions.  
Similarly, the national guidelines focus on the use of tablets, because of concern about the 
accuracy of dosing and stability of syrups.  However, syrups are favoured by many 
caretakers of young children due to the ease of administration, and the long history of using 
chloroquine syrup for children.  Several registered amodiaquine syrups are very widely 
available in Part II drug stores.  No SP syrups are currently registered in Tanzania because 
of concerns about the formulations, but some may be registered in the near future, and 
unregistered products are available in some outlets.  Again there is a need to decide whether 
to attempt to discourage their use by explaining the dangers of inaccurate dosing to 
consumers, or to accept and work with the popularity of syrup formulations by, for example, 
providing appropriate dosing information in the communication package and forcing 
manufacturers to include a measuring device in each pack (see section 4). 
 
about drugs and have no authority to take remedial measures like confiscating any 
drugs found in general stores. 
While it is against the letter of the regulations for these Part I drugs to be supplied by Part II 
outlets for the above reasons it would not be prudent to invest a major effort to stop the 
practice.   
Injectables and syringes are currently widely available in Part II drug outlets and will continue 
to be so in ADDOs.  They are usually bought and taken with the drug to the health facility 
where a health worker administers the injection.  The current disposal procedures of used 
syringes and needles by health institutions are however extremely worrying because safety 
boxes are not universally used, disposal areas are not protected and there is no equipment 
                                                 
19 in contrast to the NMCP IEC materials targeted at retail outlets prepared in 2001 for the change in first line drug 
policy, which focused solely on SP tablets.   
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for destroying the used syringes in a safe and environmentally acceptable way.  As a result 
there is:  
• An opportunity for the re-use of syringes. 
• The possibility for used syringes to be picked up and played with by children. 
• The chance for people to buy their own syringes and use them at home.  In countries 
where sale of disposables is long established, home medication with a “family 
syringe” is common. 
• An opportunity for unqualified staff at the Part II pharmacy to administer injections.  
The team found some evidence of this during the fieldwork. (See slide 37 in Appendix 
11). 
 
Action Points  
Clear alphabetical list of Part II registered brands should be supplied to all Part II 
outlets, general shops, pharmaceutical and general wholesalers and those involved in their 
inspection (Regional Pharmacists, District Pharmacists, CHMTs and Health Assistants) so 
that they can quickly check and ascertain if the products in stock are registered. 
Inspectors should be provided with lists of the drugs that are allowed by the various 
outlets so that over time they can encourage the outlets to stock only the categories of drugs 
that the regulations specify. 
The public sector must improve its stock management to ensure that Part I drugs are 
always available.   
Information to consumers and inspectors should highlight that quality of unregistered 
drugs is not guaranteed and that checking to ensure that the drugs are registered is in the 
interest of the consumers. 
A detailed assessment of injection safety needs to be carried out. 
Areas of Concern 
With regard to supervision and inspection, two regions visited had different approaches to 
supervision and inspection of drug outlets.  In Mwanza region, the Regional Pharmacist is in 
charge of the Regional Drug inspectorate.  She works closely with the District Pharmacists.  
The District Pharmacists work in collaboration with the health officers and health technicians 
who perform the actual inspection at the ward level.  In Mtwara Region, The Regional 
Pharmacist is the sole Drug Inspector and carries out the inspection with his team up to ward 
level every quarter.  No inspection is done in his absence.  He faces transport problems as 
he uses a pool vehicle only when the other departments are going out for supervision or 
inspection.  The inspectors in Mwanza use pool cars as well and the technicians more often 
than not use their own bicycles.   
With the introduction of ADDOs the PB will be directly involved as opposed to the current 
situation where the Regional Commissioners and their committees are responsible for 
registration and control of Part II outlets.  The PB will ensure that all inspectors are trained up 
to ward level and that there is uniformity in carrying out the inspection as opposed to the 
current situation where most of the health assistants have no knowledge about drugs. 
Transport is and will continue to remain a major constraint.   
 
Action Points  
Health assistants should be provided with bicycles on a lease/purchase basis. 
CHMT staff be provided with motorcycles on a lease/purchase basis. 
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7 Safety of Private Diagnostic Laboratories 
It was also observed that private laboratories are being established with increasing 
frequency.  They offer malaria microscopy at Tsh. 200.00 per test, a service rarely available 
at public facilities. 
Figure 12 
A Private Laboratory with dangerous practices 
 
Areas of Concern 
• While some laboratories are safe and well managed, some appear quite unsafe.  In 
one laboratory two hypodermic needles were being used to make finger pricks and a 
blood filled syringe was being kept in the same box as new syringes.  (See Figure 
12). 
• Some are in the same building as Part II pharmacies, contrary to Part II poisons 
guidelines. 
• The owners of Part II shops own some laboratories.  The diagnostic result may be 
biased.  This may be deliberately done to encourage the patient to buy from his/her 
outlet. 
 
Action Points  
Close laboratories which are in the same buildings as pharmacy outlets. 
Introduce stringent inspection of private laboratories. 
Educate the inspectors to recognise unsafe practices. 
Conduct a safe parenteral procedure survey of laboratories and Part II pharmacies. 
The owners of Part II outlets should not own laboratories. 
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8 Ensuring consumers and retailers have adequate knowledge 
Many studies have shown that the majority of early treatments for childhood illness are given 
at home using shop-bought brand name drugs in many countries including Kenya and 
Uganda.   Early treatments for children are given at home using brand name drugs bought 
from Part II pharmacies and general shops.   
Although a high proportion of childhood and adult fevers are caused by malaria, patients may 
only buy antipyretic analgesic drugs.  When antimalarials are used, many customers 
purchase inadequate quantities of the drug.  The reasons for this are a combination of 
ignorance and poverty.  Retailers and consumers were found to have little knowledge in the 
following areas. 
Retailers:  
• Functions of drugs 
• Correct drug dosages 
• Division of brands of antimalarials 
into generic groups 
• Danger signs 
• Adverse reactions 
• Registered Products 
• Drugs permitted to be stocked in 
various outlets e.g. which drugs are 
allowed to be in Part II pharmacies or 
general shops 
Consumers: 
• Information on various brands of the 
same drug 
• Drug dosages 
• Recognition of severe symptoms e.g.  
convulsions 
• Importance and benefits of early 
treatment 
• Adverse effects 
• Avoidance of injections 
 
There is really a potential to reduce malaria deaths if home treatment can be improved.  One 
way of achieving this is to improve the knowledge of consumers themselves.  In addition, 
train retailers to give good advice on antimalarial use and management of malaria.  This can 
only be done if their knowledge in the above-mentioned areas is improved.   
There are therefore two approaches for improving the knowledge of retailers and customers.  
The two approaches, which have been and continue to be implemented, are: 
• Communication 
• Training. 
8.1 Communications strategy 
To enable consumers to acquire appropriate and good healthcare seeking behaviour and at 
the same time to help the drug retailers acquire and improve their knowledge, strategic 
communication approaches should be designed to address the above key areas of concern.   
Various communication approaches currently being used to influence consumer and retailer 
behaviour are mainly from manufacturers or their main agents.  Although communication 
strategies have been designed and put in place by various organisations, they do not appear 
to be as effective as they should be. 
To be effective a communication strategy must be designed with specific communications 
objectives and target segment in mind.  The target audience to be addressed by 
communications strategy includes the following: 
• Parents of children under five 
• Adults 
• Owners and sellers in Part II shops 
• Owners and sellers in General shops 
• Pregnant mothers 
• Health Assistants 
• Dispensary/Health centre staff 
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• Religious leaders 
• Teachers.   
The National Malaria Medium Term Strategic Plan (NMMTSP 2003) underscores the 
importance of communication strategies on early diagnosis and appropriate treatment at 
household level.   It emphasizes the following underlying critical issues:  Knowledge within 
the communities which should be followed by timely actions to be taken in ordinary and 
emergency situations in case of febrile illnesses within the family members, especially for the 
most vulnerable groups.  The major communications objective will focus on consumer and 
retailer knowledge.   
8.2 Advertising Campaign using mass media 
Advertising is a popular method of impersonal communications using such mass media as 
newspapers, magazines and journals, TV, radio, billboards and posters.  The role of an 
advertising campaign will be to educate and evoke and associate specific feelings and 
emotions about malaria and connect them to the early treatment using quality antimalarials at 
the right dosage.  In other words the campaign would set the right attitude for the 
management of malaria both at the retailer and consumer level.  Focus on attitude is 
important because attitude influences behaviour and behaviour determines result.  
Advertising requires heavy repetition to build the associations, hence it is necessary for 
advertising to be consistent over time if it is to have any meaningful effect.   
Our findings during the fieldwork were that: 
There was no consistency in advertising nationally because the few organisations in the 
market have limited their activities to pilot areas, e.g. CARE Tanzania confine themselves to 
pilot areas around Dar es Salaam.  Other organisations include NMCP whose advertising 
through the posters focuses on the public sector.  Posters are mostly placed in public health 
facilities and are not replaced regularly.  The effect of such posters is probably minimal.  
Advertising through the press is expensive and thus little used.   
A review of CARE MALIP IEC strategy (2000-2003) showed that they focused mainly on: 
• Bed nets 
• Pilot urban and peri-urban areas in and around Dar-es-Salaam 
• Use of Posters and occasional use of T.V.  and radio media for advertising and rarely 
any press advertising campaign. 
A review of ADDO marketing Plan (January 2003-December 2003) revealed that advertising 
through various media would be well covered when SEAM project on communication is 
launched, although they too would focus on a pilot area.  The ADDO plan will be prepared 
annually.  A year is a very short period in which to achieve behavioural change so it will be 
crucial that the ADDO plans are consistent over a number of years, otherwise behaviour 
change will be limited.  Advertising through the radio is planned to run for nine months with a 
break of three months.  It may be more effective if the radio campaign were allowed to run for 
two years with a three month break in the middle.  PSI have wide experience advertising the 
ITN campaign and have been promoting ITNs successfully for a considerable time. 
8.3 Media Strategy 
Whether it is an advertising or editorial campaign, careful analysis and selection of 
appropriate media are fundamental to the success or failure.  Deciding to include advertising 
or editorial campaigns in the communications mix is a relatively easy decision compared to 
deciding which media and specific media vehicles (e.g. specific magazine title) to use.  
Should press, T.V., radio, cinema or posters be used?  If so, how much of each? Should they 
be mixed together (media mix)?  If press advertising is chosen, which publications should be 
used – national dailies, daily or weekly regional papers, or magazines? How many times 
should the audience see or hear the advertisement? (Optimum frequency)  Even a great 
advertisement will not work if, a) it is in the wrong place, b) It is placed at the wrong time, or 
c) it is at the right place at the right time but not enough times (insufficient frequency). 
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Most of an advertising budget is spent on the media (and not on the creative side or 
production side).  For an advertising campaign to succeed careful attention to detailed media 
planning, knowledge and negotiation skills is very important.  Therefore it is necessary to use 
expert media planners and buyers and get the best out of advertising by finding the right 
spaces or places for an advertising campaign at the lowest cost. 
With this in mind we now focus on the criteria for selecting the various media/channels 
available that can be used to communicate with the rural community using advertising.   
Radio 
Information available from various organizations, e.g. Care Tanzania’s MALIP IEC Strategy, 
involved in advertising as a communication tool was that a radio programme or campaign 
has been and still is effective in communicating basic information to the rural and urban 
communities and is appropriate to less literate people.  During our meeting with PSI senior 
staff corroborated our finding that radio use is widespread in the community. 
Other benefits of using radio cited by the above organisations are: 
• Radio allows malaria messages to reach large numbers of people on a national level 
because radio ownership is widespread and several neighbours can use one radio. 
• It can easily be carried to the place of work, particularly to the gardens in the rural 
areas. 
• Listeners have relied on radio and still rely on radio for initial awareness creation.  
Once they become aware, individuals may seek to validate the radio message, 
evaluate it and obtain clarification, for example through interpersonal consultations 
and reading newspapers before they take action on the malaria message.   
• Despite the benefits of radio as a medium of communication, not only for advertising 
campaign but also for other educational campaigns, there are certain limitations, 
which dictate the scope and content of the subject it can relay effectively.  The 
limitations, which need to be taken into consideration when using the radio as a 
medium for communication, are as follows: 
o It is a one-way channel of communication without immediate opportunity for 
asking questions or seeking further clarification. 
o The programmes are impersonal so they stand a risk of not being taken seriously 
to some extent and may face criticism when certain sensitive malaria issues like 
adverse effects are discussed. 
o The programmes are sometimes too rushed. 
o It is difficult to know that the message broadcast is the message that the listener 
understands. 
o The language may not be understood because it is too technical for the average 
person. 
The above limitations support the fact that for subsequent sources of information, people rely 
on a combination of other information, education and communication sources. 
The radio programme alone, though a very effective one, does not therefore provide the rural 
population with all the information they need in order to make major decisions leading to 
behaviour change on home treatment of malaria. 
Television 
Television has sound, colour and movement, which makes it an ideal medium for 
demonstrations but its ownership is restricted to urban and some peri-urban areas .  T.V.  
ownership in rural areas is very limited.  The current providers in the market use it and have 
planned to use it to a very limited extent.   It would therefore offer limited effect since the 
main target is the rural population. 
Other channels available for advertising campaign:  
Newspapers 
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A review of various documents e.g. MALIP IEC strategy and a discussion with Shelys 
pharmaceuticals and PSI staff revealed that the use of newspapers as a medium of 
communication has not been exploited fully.  No explanation seemed to have been 
forthcoming from them.  The assessment made during our fieldwork indicated that this is due 
to: 
• Irregular availability of newspapers in remote rural areas. 
• Poor people cannot afford a daily newspaper.   
Despite the above limitations of the newspapers, they are still a useful way of communicating 
the malaria messages because: 
• Information can be referred to or retained for future sharing. 
• Useful sources for information for those who are not able to listen to the radio or 
watch T.V.   
Posters 
It was established that all organisations use posters extensively as a medium of 
communication as they are visual and can be retained for a long time for reference.  They 
are a good channel of communicating information to 
the community.  The unfortunate thing is that the 
messages reaching the rural population through 
posters with regard to information on antimalarial 
drug dosages is conflicting.  This is because the 
majority of the posters prepared by the NMCP in 
accordance with their guidelines goes to the public 
facilities and rarely reach the private shops.  Many of 
the posters in Part II pharmacies and general shops 
we encountered were either faded, torn or defaced 
(see Figure 13) indicating that they had been in place 
for a long time and were not printed on sufficiently 
robust media.  The retailers rely mainly on 
manufacturers’ posters, some of which do not give 
dosage instructions as required by the National 
Guidelines, hence confusion in dosing. 
Figure 13 
Counterproductive Advertising 
Bill Boards 
These are used mainly by PSI for mosquito nets and insecticides for treating nets.  They are 
highly visual but with limited space for conveying messages in the case of malaria knowledge 
and management.  It would not be effective as a channel of communication in the first year 
but it would be very useful as a reminder in the second year. 
Table 8 below gives an idea of media characteristics .  It gives a guide as to what media 
should be used and about how much it would cost to use them.  Other cost estimates can be 
derived from communications activities budget (MALIP IEC strategy (2000-2003).   
 
Table 8 
Summary of Media Characteristics 
Press and Media   
TV 
 
Radio Daily Regional Posters Bill boards 
Audience 
Size 
Medium.  
Limited to 
urban and 
peri-urban 
areas 
Very large 
National 
coverage 
Large 
national 
coverage 
Small 
No national 
coverage 
Difficult to 
coordinate 
on National 
scale. 
National 
Coverage 
Audience Wealthier Mass National Geographic Private and Mass 
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Type Urban 
and Peri-
urban 
audience. 
Many house 
wives. 
Commuters 
and rural 
people 
mass 
audience 
but less 
likely 
amongst 
the poor 
people 
mass 
audience 
but less 
likely 
amongst 
the poor 
Public 
Health 
workers. 
audience 
Cost of 
Production 
High High Low-
medium 
Low Medium Very high 
Minimum 
Cost of 
space 
High Low Medium Low Low 
medium 
Medium 
Cost per 
1000 
population 
reached 
More than 
Radio 
Low Low-
Medium  
Medium 
 
Variable 
depending 
on the size 
of posters 
Very Low  
Extra 
Advantages
Adds 
credibility 
to the  
Message 
Transportable 
medium 
Retained 
message 
Retained 
message 
Retained 
message.  
Can be 
used for 
various 
purposes 
e.g.  road 
shows 
Highly 
visual 
• Cost of Production. Development and production of messages, actors involved and 
the right colour required depending on whether it is for T.V., radio or posters. 
• Minimum cost of space. Advertising space is rarely bought in single units.  The space 
is normally bought over a period of time and not one-off. 
• Average cost per thousand. This is the cost of reaching at least 1000 of the 
population audience.   
8.4 Publicity 
Publicity is a communications technique that uses print and electronic media to convey 
messages without being paid for.  Positive publicity is dependent primarily on good 
relationships with the media.  Publicity should be integrated with the other communications 
elements: e.g. follow up of advertising campaigns with press launches and publicity 
campaign to maintain the visibility generated by the public relations people. 
During the fieldwork, all the communication plan documents reviewed were found to have 
totally ignored publicity.  As a tool which should be integrated with other communications 
elements, omitting it in the said plans and even ignoring it, as is the case in those plans, 
denies other communications techniques synergistic effect.  The only organization that has 
so far considered this area is CEEMI.  It organized a workshop on malaria and the media.  
This workshop was organized on 28th October–1st November 2002 with the aim of bringing 
the media closer to NMCP as partners.  According to the workshop report (December 2000) 
the meeting aimed to enhance a multi-directional advocacy and education programme aimed 
at promoting malaria as a newsworthy topic amongst those working in the media at all levels, 
and to improve policy and practice concerning the depiction of malaria in the print and 
broadcasting media.  It was quoted in the report that the journalists who attended the 
meeting had a number of questions and concerns, focused on: 
• Lack of transparency by the Ministry of Health. 
• Uncooperativeness and slow response by the MOH when it comes to releasing 
information. 
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This was an excellent start to using publicity.  It appears that no follow up is being done to 
ensure that there is consistent contact using a public relations agency to enhance this very 
important communications tool.  Identifying one individual at NMCP to play the role of a 
public relations person would promote the use of this communications tool effectively by: 
• Ensuring immediate response to media houses. 
• Ensuring that any information worthy of publicity is conveyed to the media houses. 
• Quarterly meetings/workshops between NMCP and all journalists from the media 
houses mentioned under media strategy are held to review performance and 
relationships. 
• A public relations firm is engaged and contacted at least once a quarter to review the 
outcome generated by publicity and to put in place what should be done in the next 
quarter. 
This approach will ensure that negative publicity like the one currently dogging SP20 is 
controlled and managed effectively. 
8.5 Interpersonal Communications as a strategic option 
An interpersonal communications approach, although conventional, is one of the most 
effective ways of disseminating information to consumers and retailers.  It is considered 
appropriate because it reinforces the impersonal communications approaches as follows: 
• Provision of an opportunity for the consumers and retailers, and even the health 
workers, to have a two-way dialogue where people ask questions which they would 
not be able to ask while listening to the radio or in a group discussion.   
• Provision of reassuring personal touch. 
• Provision of instant feedback from the consumers and retailers. 
• Opportunity to respond to consumers’ and retailers’ changing needs, moods and 
questions. 
During the discussions with PSI it was established that they have effectively used their field 
representatives to provide information and educate clients on malaria management and 
prevention using ITNs.  Their clients include pharmacy retailers and wholesalers, general 
shop retailers and general wholesalers.  Other organizations like CARE have gone further to 
use their staff to disseminate information not only on the use of ITNs but also to pass 
information on antimalarial dosages, importance of earlier treatment and the management of 
malaria at the consumer and Part II pharmacy levels. 
However, interpersonal communication is expensive, as it requires extensive manpower 
mobilization and training, despite the fact that it is a tool that ought to be used to augment 
impersonal communications.  Because PSI and CARE have the manpower and the capacity 
and a wide network in the country, they have and continue to use interpersonal 
communications, using their personnel effectively:  Other channels which could be used 
effectively for interpersonal communications include: 
• Field Health educators 
• Religious organizations 
• Health Personnel 
• Teachers. 
The above people were cited as the most appropriate groups to handle interpersonal 
communications due to the respect they command in the community.  Following are some 
suggested activities which could be implemented using the above channels. 
For teachers to be effective, ensure that: 
 
20 There have been a number of articles highlighting the adverse effects of Stevens Johnson Syndrome linked to 
SP.  These have been very damaging and discourage people from using SP. 
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• Teachers participate in malaria seminars. 
• Ensure that posters with full malaria information are distributed to teachers in schools. 
• Provide a slot for malaria programmes in school radio programmes. 
• Health officials visit schools at least once a term to give short lectures on malaria and 
replenish the posters where necessary. 
Ensure that religious organizations have posters and encourage them to talk regularly to their 
congregations about malaria and its management. 
We found out that the most popular interpersonal communications channels being used by 
PSI and CARE are:  
Folk Media 
Folk media, which includes songs, poems and plays, was another channel of 
communications identified as an effective means of communicating malaria information.  
Popularity of the folk media was identified as the single most important advantage in using 
the channel.  It was cited as the medium that would bring messages to the community 
without offending anyone.  Composed songs, plays and poems could be acted, recited or 
performed during traditional festivals and national functions.  Various events like soccer 
matches could be sponsored and folk media used to convey malaria messages to the 
community during such occasions.  It is cost effective as the actors are normally found in the 
community and do not have to be transported from one place to another.  Unlike many other 
suggested channels of interpersonal communications the community sees no disadvantages 
in using the media to communicate malaria information. 
Exhibitions/Road shows 
This media was cited as growing very fast in popularity amongst the community and health 
workers and is compatible with folk media.  It is dynamic and combines the benefits of 
interpersonal communications, plays, visual and audiovisual aids.  It involves the mounting of 
music systems, videos, on a track as well as posters with various performers performing 
different plays as they move from one place to the other.  It is quite infectious and pulls a 
very large crowd particularly in the rural areas.  The cost is a bit high, hence some 
organisations use it cautiously.  PSI has implemented this strategy successfully.  It is 
recommended that this medium be used to launch a campaign and thereafter for follow up. 
8.6 Communications agencies, firms, and organisations currently involved in 
communications 
8.6.1Organisations 
NMCP  
NMCP has produced a series of malaria control booklets that spell out malaria policy 
guidelines with full information on malaria, its prognosis, diagnosis and treatment.  There are 
also comprehensive training manuals that are focused and clear.  Distribution of these 
materials has mainly been confined to the public institutions.  Unfortunately many of these 
materials, including the National Guidelines, are now out of print.   
IEC materials were also produced by NMCP in sufficient quantities in the year 2001 for policy 
change.  The main limitation is that their availability in Part II outlets is very limited and they 
are rarely seen in general shops.   
A concerted effort should be made to ensure that adequate malaria posters are available in 
the private sector. 
Although comprehensive information and education and fair communication efforts have 
been made by NMCP, the influence on provider behaviour seems to be skewed towards 
public healthcare providers, leaving the private healthcare providers in the hands of the 
manufacturers and /or their agents.  Since the majority of the consumers seeking malaria 
treatment first go to the private healthcare providers, particularly Part II retailers, the 
consumers’ awareness and knowledge are influenced by them.  Consequently, there is a gap 
in the private sector that needs to be filled if home management of malaria is to be effective.  
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The following organizations have striven and continue to strive to fill the gap using various 
communications strategies and approaches. 
CARE TANZANIA  
They run Malaria Intervention Project (MALIP), a project limited to four Districts in Dar es 
Salaam Region and focused mainly on urban and peri-urban areas.   
In their project implementation report  (July 2001-2002) three important communication 
activities dominated the activities: 
• Collecting of IEC materials that carry malaria intervention messages from NMCP and 
PSI and distributing them to the community members. 
• Using mass media (mainly posters) to disseminate malaria messages to the 
community in the project area. 
• Using plays, songs and poems to pass malaria messages across to the community 
members in the pilot areas. 
CARE has made attempts and continues to work with NMCP and PSI and to use 
communication interventions to reach the community.  However, their activities are limited to 
the pilot areas.  In addition the pilot areas are within urban and peri-urban areas, hence their 
activities do not address the problems facing the rural population. 
CARE Tanzania MALIP Project phase two is planned to cover Mwanza, although this has not 
been finalized. 
CEEMI 
CEEMI recognises media houses’ mainly electronic and print media as one of the most 
effective ways of getting to the targeted audience.  Because of this recognition, it recently 
organized a workshop for journalists.  The participants came from all over East Africa. 
This is a commendable step forward as media relationship strategy is a key approach to 
managing some of the damaging reports that can otherwise create a permanent damage to 
consumer and retailer behavioural change efforts, e.g. recent print media negative report on 
SP.  Besides, maintaining such a relationship is a sure way of ensuring that the correct and 
clear messages on malaria reach the people.  NMCP should therefore work closely with 
CEEMI towards this goal. 
PSI 
PSI uses high profile integrated social marketing techniques with regard to insecticide treated 
nets and their insecticide brand used for treating nets. 
During the discussion with the PSI management the following key areas of their activities 
were cited: 
They have divided the country into zones.  This has been done not only for ease of product 
distribution purposes but also for ease of interpersonal communications, e.g. road shows, 
theatre and sponsorships.  The zones are: 
Lake Zone 
Southern Zone 
Central Zone 
Dar es Salaam Zone 
They said that they work closely with Medical Stores Department.  MSD store their products 
centrally in Dar es Salaam.  They then use their own trucks to transport the goods to MSD 
zonal stores from where the products are moved to regional wholesalers and finally to the 
District sub-wholesalers. 
It was cited that this arrangement is also convenient for communications purposes because it 
allows for ease of transporting IEC and promotional materials to all parts of Tanzania. 
During the discussion, we were informed that PSI has commissioned a consultancy firm 
called Research International which works with the PSI research team to handle issues like 
the management of demand pattern, stock and market structure, and more so consumer 
behaviour, and assessment of the impact of IEC.  With a research consultancy firm and a 
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research team in place, PSI has a good understanding of Tanzania’s consumer market and 
is well placed to assess the impact of IEC on a continuous basis. 
They did spend time on product positioning, pricing, distribution policy development and 
finally the development of promotional or marketing communications strategy.  The main 
strategic communications options currently being used by PSI are as follows: 
• Interpersonal communications using field health representatives 
The four marketing zones have given them an easy way of reaching their clients with 
interpersonal communications effectively.  The health representatives work with 
general and pharmaceutical wholesalers, drug and general retailers and the 
community by offering expert advice.  This is viewed as a longer-term strategic 
partnership win-win scenario.  This strategy is working extremely well. 
It is expensive, as it requires extensive manpower mobilization and training.  However 
PSI has a well-trained field force and a good network of distributors, hence they can 
reach as many retailers and community members as possible. 
• Communication through folk media 
Use of songs poems and plays is an effective way of communicating to the rural 
people.  PSI uses this approach effectively to reach the community.  It is very 
effective in various cultures and can have an immense impact on the community.  
During our meeting they said that they normally use theatre groups.  They said that 
the groups were available locally and that they need not spend money to transport 
them to different locations. 
• Exhibitions/Road shows 
This is an effective and efficient way of reaching the rural drug retailers and the 
community at large.  It combines the benefits of interpersonal communications, plays 
and visual aids.  PSI has implemented this strategy successfully.  They use three 
different organisations across the country.  
They explained that they would use 600 road shows in the year 2003. 
Impersonal Communications Media (Mass Media) 
It was cited that radio and posters are used extensively and that they use the services of 
various communications agencies for: 
• Planning/strategy 
• Creativity 
• Media Choice. 
It is important to note that the agency selection procedure is a time consuming, tedious 
process involving the following: 
• Definition of the requirements 
• Developing a pool list of attractive agencies 
• Credentials pitch by the agencies 
• Issuing of brief to shortlisted agencies 
• Full agency preparation or pitch 
• Analysis of pitch 
• Selection of winner 
• Agreeing on contract details announcing a winner. 
Apparently, PSI has selected and tested the competence of the agencies it uses.  
They seem to have developed good relationships with the selected agencies over a period of 
time.  This good relationship coupled with being a large client has attracted a reasonable 
discount. 
PSI’s communication model is the most successful one because of the following: 
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• The success of using one communication tool is normally hampered by its 
constraints.  PSI integrates all communications elements to minimize individual 
strategy constraints. 
8.6.2 Communications Agencies  
Appendix 9 lists the communications agencies which can be contracted for communications 
purposes through a transparent tendering process. 
Although it is not listed as one of the communications agencies, Dunia Promotions Ltd. was 
mentioned by PSI as one of the most effective agencies in Tanzania, having successfully 
been used by PSI themselves, Vodafone, Tanzania and Kibo Breweries. 
According to PSI, selection was based on the rigorous agency selection procedure and that 
the agencies selected are specialized in certain areas of communications, e.g. Momentum 
Exp. DMC and Group Africa is specialized in road shows.   
When we met the top management of PSI for the second time, they were asked what they 
thought about funding of communications activities.  They responded as follows: 
• The public health sector has more than they can manage.  To get more involved in 
the private sector initiative will be fertile. 
• Funding must originate from NMCP and not from the districts.  Not much will happen 
if funds are to originate from the Districts. 
There are two options for using organizations to implement communications activities: 
• NMCP directly hiring a range of Communication Agencies. 
• Using one agency with media planning, knowledge and negotiation skills to manage 
the project and subcontract the various specialised communications agencies 
needed. 
The latter approach may appear expensive, but may end up being cost-effective, because 
NMCP does not have the in-house capacity to select and manage the diverse range of 
communications agencies needed. 
The process of designing and implementing the communications strategy would be as 
follows: 
1. Identify and fill key gaps in evidence/information to develop the strategy, for example, 
in different users’ behaviour, media habits, provider behaviour. 
2. Develop a coherent communication strategy. 
3. Develop partnerships taking account of complementarity and comparative 
advantages. 
4. Set campaign objectives and strategy. 
5. Divide Terms of Reference into lots 
a. Behavioural studies 
b. Provider behaviour 
c. Media habits 
d. Creative development 
e. Road shows 
f. Training  
g. Communications. 
6. Campaign Management and monitoring and evaluation including media monitoring. 
 
Areas of Concern for patients 
In summary: 
Inadequate information/Knowledge by consumers on:  
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• Drugs 
• Drug dosages 
• Prices 
• Recognition of severe symptoms e.g.  convulsions 
• The importance and benefits of early treatment  
• Adverse effects 
• The avoidance of injections. 
 
 
Action Points  
Use commercial marketing strategic approaches described herein to be run by outside 
agencies. 
Use road shows to be conducted in each area on an annual basis (not one-off push).  
Integrate these shows with other media in a co-ordinated and sustained campaign. 
Involve sellers in Part II and general shops, healthcare workers fully in road show 
activities. 
Discuss the need to redesign NMCP IEC materials to include amodiaquine tablets and 
syrup as well as SP on the basis of MOH decision on this issue.  A brochure and price list of 
activities and materials should be sent to the Districts.  They can then order the materials 
through NMCP and pay for them out of the basket fund. 
Laminate IEC posters for Part II and general shops (paper posters are counter productive 
because they are easily destroyed).  
Develop and produce “top pocket” size laminated dosing cards and promotional 
material like T-shirts, kangas, caps etc. for consumers.   
Work closely with manufacturers and encourage them to step up their poster and 
appropriate dosing campaigns. 
Work with CEEMI to cultivate and sustain media relationship with the aim of creating an 
avenue for sustained publicity and editorials as well as damage control. 
Areas of Concern for retailers 
In summary 
Inadequate knowledge by retailers about:  
• Function of Drugs 
• Division of brands of antimalarials into generic groups 
• Correct Dosing 
• Danger Signs 
• Adverse effects. 
 
Action Points  
Both Part II pharmacy workers and general shopkeepers must be involved in the road 
shows.  They can be brought in before the road show is presented to the public to be given 
specific training and then involved in the road show, so that the public see them as being 
knowledgeable and a part of the health care system. 
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9 Making General Sale Antimalarials Affordable to the Majority 
9.1 Retail Prices for Antimalarials 
Table 9 shows current retail prices for commonly available antimalarials.  SP (Sulphadoxine 
Pyrimethamine) is the cheapest treatment on offer, ranging from 120/= to 900/= for an adult 
dose.  Most East African SP brands are sold in the range of 300/= to 500/=, with the 
originally patented European product, Fansidar, commanding around double this price.   
SMP has the same action as SP, but a slightly different formulation. 
Sulphamethoxazole Pyrimethamine.  Often perceived as a different drug by consumers, it is 
generally sold at a higher price than SP, especially for the originally patented European 
product, Metakelfin.  Amodiaquine tablets are generally slightly more expensive than SP, 
with a range of 400/= to 800/= per adult dose.  Quinine is the most costly, generally over 
2000/= for 42 tablets, although this full adult dose is rarely purchased in practice.  These 
figures compare with a standard market rate for an adult dose of chloroquine tablets of 100/= 
before the change in first line policy.  Syrup and injectable formulations are generally more 
expensive than their tablet equivalents. 
Table 9 
       Retail prices for an adult dose of widely available antimalarials tablets (Tsh) 
Antimalarial Adult Dose1 Retail Price Range for Adult Dose (Tsh) 
SP 3 tablets 120/= to    900/= 
SMP 3 tablets 750/= to 2,100/= 
Amodiaquine 8 tablets 400/= to    800/= 
Quinine 42 tablets 1,260/= to 4,200/= 
Sources:  
1 National Guidelines for Malaria Diagnosis & Treatment  
2 Field visits in February/March 2003 
Key Concerns 
Antimalarials are not affordable to much of the population.  This is demonstrated by two 
treatment seeking behaviours, both or which have potentially damaging health 
consequences: 
• Consumers frequently purchase less than the full dose, especially for amodiaquine 
and quinine. 
• Consumers with fever often buy only painkillers, such as paracetamol and aspirin, 
when they have fever, which are much cheaper at an average price of 10/= and 5/= 
per tablet respectively.  This is a particularly common strategy in the early stages of a 
febrile episode, with a tendency to wait and see if the illness is self-limiting before 
proceeding to purchase antimalarials.   
These two behaviours are not solely related to affordability.  Even with cheaper retail prices 
some consumers may choose not to buy a full dose of an appropriate drug because either 
they are not aware of its importance, or because they decide to take the risk of developing 
more severe disease in the hope that they will be able to save their scare resources.  
However, if the prices of SP/SMP and amodiaquine were reduced, we would expect 
significant increases in the proportion of febrile episodes treated with an antimalarial, and the 
proportion treated with a full dose. 
9.2 Can SP and Amodiaquine Retail Prices be Reduced? 
Possible sources of retail price reduction are listed below, with an assessment of their 
feasibility in this context21.   
                                                 
21 The Pharmacy Board has commissioned a Drug Pricing Study from the Faculty of Pharmacy at the University of 
Dar es Salaam to investigate different mechanisms for reducing drug prices.  Once complete, this should be 
carefully reviewed to assess the implications of their findings for general sale antimalarials. 
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• Reducing manufacturing costs through higher volume production? While the 
proposed communication package should increase Tanzanian demand for SP and 
amodiaquine (see section 8), there are unlikely to be substantial reductions in 
manufacturing costs, as current production volumes are already high, and many East 
African manufacturers serve the international market, and will not be heavily 
influenced by Tanzanian demand alone. 
• Reducing manufacturing costs through a reduction in packaging costs? This is 
unlikely to occur, and would not be desirable.  In fact several of the recommendations 
of this report may serve to somewhat raise packaging costs, through the increased 
use of blister packs and improved labelling and instructions (see section 4). 
• Reducing retailer overheads? Retailers must recoup a wide range of overhead 
costs, including staff, transport, taxes, licence and permit fees, and rent.  The ADDO 
programme plans to explore two possible strategies for reducing overheads for drug 
stores: first of all providing tax breaks to accredited stores, and secondly reducing 
travel costs for drug sourcing by linking ADDOs with a prime drugs vendor or 
developing an ADDO purchasing organisation.  These initiatives may help to reduce 
antimalarial retail prices, at least within ADDOs.  However, the ADDO programme will 
take several years to go nationwide, and will not address the costs of general shops.   
• Reducing mark-ups? In view of the above-mentioned overheads, a significant mark-
up is obviously required for shops to cover their full costs.  However, there is some 
indication that mark-ups on SP may be unnecessarily high, allowing shopkeepers to 
reap abnormal profits.  For instance the retail price of locally manufactured SP is 
between 3.3 and 5.5 times its factory gate price.  The breakdown of this mark-up is 
shown in Box 2, indicating that retailers take the lion’s share, with a mark-up of over 
100%.  This is much higher than the overall mark-up for locally manufactured 
amodiaquine, for which the retail price is between 2.1 and 2.8 times the factory gate 
price.  This indicates that, at least for SP, there may be potential to reduce mark-ups, 
particularly at the level of the final retailer. 
• Encouraging use of cheaper brands.  Some consumers are willing to pay two to 
three times the price of the cheapest brand in order to buy a more valued product, 
particularly for well known brands from European companies.  This reflects concern 
about the quality of cheaper drugs, especially those manufactured in Tanzania and 
India.  Available evidence on drug quality indicates that this has been justified in 
several cases in the past (See section 3).  However, once a quality assurance 
programme is fully established in Tanzania, including GMP standards for all 
manufacturers and routine quality control testing of all antimalarial batches, these 
problems should be much reduced and hopefully eliminated.  Once this is achieved, a 
communication campaign to explain that the brands belong to the same generic 
group (i.e. all SP brands contain the same drugs), and that all registered brands are 
of high quality, will reduce the potential for higher mark-ups on some brands, and 
help to reduce the economic burden of treatment. 
(Prices could also be reduced through government or donor subsidies.  Due to the 
substantial operational difficulties involved in such a strategy this is not considered a viable 
option for the current first and second line antimalarials, but is discussed in Section 12 in 
relation to the more expensive combination therapies that the government plans to 
introduce.) 
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Box 2:  Tracking the Price of SP through the Distribution Chain 
The table shows the price at which an adult dose (3 tablets) of a locally manufactured SP 
changes hands as it moves down the distribution chain, and the mark-up obtained at each 
stage. 
Table 10 
Mark-up on SP 
 
Source: Field visits Feb/March 2003 
 
Action Points  
Strategies should be adopted to push down mark-ups where they are excessive by providing 
information to consumers and increasing competition in the market: 
Publicity campaign to push down SP prices.  A key  
component of the communication package should be  
increased awareness of appropriate prices to pay for the  
first line drug, e.g.  “don’t pay more than 200/= for  
three tablets of SP”.  This must be combined with IEC  
materials and packaging that indicates clearly which  
brands fall under which generic category.  The publicity  
campaign should include posters giving recommended  
retail prices for general sale antimalarials.  This is  
already done for cigarettes.  (See Figure 14).  Although  
most drug manufacturers or importers provide distributors  
with schedules of recommended wholesale and retail  
prices, these are treated as suggestions only, and are not  
enforced.  Retailers are generally totally unaware of the  
recommendations.  This could be addressed by printing  
recommended prices on product packaging (as PSI do  
with their socially marketed products), but commercial  
manufacturers are unwilling to take this step unilaterally,  
in case it makes their products less attractive to retailers. 
An alternative would be to produce generic advertising 
materials listing recommended prices for SP. 
The main East African manufacturers may be willing to include their brand names on the 
poster in return for the additional publicity they would receive, especially as such price 
maintenance is likely to increase their profitability by increasing sales at a constant factory 
gate price. 
Encourage more general shops to stock SP (and amodiaquine if this is decided).  
Expanding the range of shops stocking these antimalarials should increase competition and 
drive down prices where mark-ups are high (see section 10.1). 
Figure14 
Cigarette Price List 
41  
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Reducing Government facility prices for SP and amodiaquine.  In many government 
PHC facilities all services are provided free.  However, some districts have begun to 
introduce “cost-sharing” for drugs including first and second line antimalarials.  In a 
Kilombero dispensary patients were charged 300/= for an adult dose of SP (and in addition 
were required to pay a 200/= consultation fee).  This represented a huge 8 fold mark-up of on 
the discounted price at which the drugs were purchased by MSD, apparently a deliberate 
strategy to allow cross-subsidisation of other more expensive drugs, such as Benzyl 
penicillin.  This is an entirely inappropriate strategy for the first line antimalarial in 
government facilities, and eliminates the potential to exert downward pressure on prices in 
the retail market.  In view of the additional travel and waiting costs incurred by patients 
visiting health facilities, Government price schedules should be revised to ensure that the 
total direct cost of treatment is at a minimum not more expensive than care from shops, and 
is preferably substantially cheaper.   
10 Role of training 
In 1998 Care Tanzania completed its urban Livelihood Security Assessment (ULSA) for Dar 
es Salaam, covering low-income households in six wards in Dar es Salaam Region.  In 
undertaking the ULSA, malaria featured prominently as the commonest problem in all the six 
wards.  Based on this, CARE is now managing malaria intervention projects in the six wards.  
The selected six wards were mostly in urban and peri-urban settings.  The overall project 
goal was to bring about significant reduction to malaria related morbidity and mortality, 
especially in children under the age of five years and pregnant women.  (Training needs for 
Self-protection and Malaria Case Management, October 2001).   The emphasis was on 
protecting the project target group against malaria using Insecticide Treated Nets and 
strengthening malaria case management.  One of the interventions for accomplishing the 
above was through training of selected healthcare providers, ward committee members, 
pharmacists, Part II pharmacies retailers, traditional healers and traditional birth attendants. 
The exercise was therefore undertaken in order to identify training needs for the different key 
groups listed above so that their services could be improved and hence contribute towards 
the achievement of the desired goals of protecting mothers and their young children from 
malaria.   
The training needs assessment indicated that Part II drug retailers or drug store vendors’ 
training needs included: 
• Stocking of the right antimalarial drugs 
• Lack of information about the use of antimalarial drugs. 
From the information spelled out above, it is evident that lack of knowledge of antimalarials 
and the management of malaria in general is not only confined to the rural areas but is also 
present in the peri-urban and urban settings.  However, those living in these areas have 
access to healthcare from numerous sources because of better health infrastructure.  Even 
then, this is a minority and efforts should be made to spread this kind of activity by CARE in 
the rural areas. 
Based on the outcome of the training assessment, CARE continues to run training on malaria 
management and prevention in six Wards in the Dare es Salaam Region under its Malaria 
Intervention Project (MALIP).  Table 11 shows those people who have so far been trained on 
malaria case management.  
Information derived from  the MALIP report of July 2001-June 2002) indicated that the 
following observations were made during the training: 
• Most healthcare providers did not know what the abbreviation SP stood for. 
• SP is given as a single dose according to the National Malaria Guidelines, but a good 
number of prescribers follow some manufacturers’ guidelines which recommend 
repeat dose after one week.  Health workers have more faith in manufacturers. 
• The use of a teaspoon in measuring the medicine is not an appropriate method. 
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Table 11 
Categories Trained in Malaria Case Management 
Non-technical Health care Providers Number trained 
Ward Health and Environment committee members 191 
Ward Peer Health Educators 153 
Ward Traditional Birth Attendants 82 
Ward Traditional Healers 33 
Technical Health care Providers 
Ward Laboratory Staff 36 
Ward MCH 45 
Ward Health and environmental Health Officers   4 
Ward Clinicians 57 
Ward Pharmacists 14 
Source: Malaria Intervention Project (MALIP): Project Implementation Report July 2001-June 2002  
 
The observations actually corroborate our findings during the fieldwork and thus the urban 
and peri-urban areas face similar problems.  Therefore the steps Care is taking to train the 
health care providers and the key community opinion leaders are relevant to NMCP needs.    
CARE uses Manual for drug retailers (malaria control series number 9) and Manual for 
trainers of drug retailers (malaria control series number 10), both prepared in the year 2000.  
They are comprehensive and to the point and thus they are quite suitable for this kind of 
training. 
Although further similar training is planned for the same wards and Mwanza Region as 
explained during our meeting, there seems to be a slow implementation of the training 
suggesting that the rural areas may not be covered in the medium term.  Consequently, 
some urgent malaria messages may not reach the rural areas unless communications 
activities are intensified through the mass media.  It is therefore pertinent to implement 
nationwide communications activities to supplement this very training that is quite relevant to 
the NMCP requirements. 
MSF 
MSF Has been running and continues to run training for drug retailers on malaria 
management in Kigoma.  Their training is not only focused on Part II drug retailers but also 
on general shop drug retailers. 
Further similar training is planned for the same region and Mtwara Region. 
On reviewing their curriculum for training of drug retailers the following observation was 
made: 
They borrowed heavily from Vicki Marsh’s working draft of 8th April 2002 for training drug 
retailers in Kenya22.  While this would be applicable to training general shop retailers, its 
contents are not suitable for Part II drug retailers because they already have reasonable 
medical back ground.  Secondly, Part II retail shops are growing rapidly and they stock a lot 
of different antimalarial drugs, hence they will form the core of home treatment for malaria.  
In Kenya, home treatment of malaria is confined to general shops where retailers have no 
medical background at all.  The training approach is therefore different, hence replication of 
such a training approach to Tanzania may not be relevant to NMCP needs. 
                                                 
22 Marsh V.M. et al. Changing home treatment of childhood fevers by training shop keepers in rural Kenya. 
Tropical Medicine & International Health. 4 (5) 383-389 May 1999.  
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While it is appreciated that MSF is doing a commendable job, it is recommended that they 
tailor their training programme to conform to the National Malaria Guidelines when 
implementing their planned training programme for Mtwara. 
MSH 
In the report on the Assessment of the Tanzania Pharmaceutical Sector, co-sponsored by 
the Ministry of Health and MSH, carried out in April-May 2001, it was proposed that there 
would be training and continuing education for ADDO drug retailers countrywide.  This 
training would be used as the criterion for accrediting any health worker wishing to work in 
ADDO. 
The accreditation course would involve: 
• Education on ADDO drugs in their generic and branded forms 
• Common indications and contraindications 
• Common dosages  
• Adverse effects 
• Information to patients on malaria and how to use antimalarial drugs 
• Laws governing their work. 
Pharmacy Board approved institutions such as the School of Pharmacy would offer such 
courses. 
Certainly, the area of concern intended to be addressed by the communications strategy 
here is retailers’ limited knowledge.  Two issues arise from this proposed training: 
The question is, how soon will MSH/SEAM implement this training programme for the current 
Part II pharmacies, which need urgent attention? 
Immediate and even medium term consumer behaviour change is not addressed by this 
training because other healthcare workers closer to the community as well as some key 
members of the community are not catered for to enable them to address the consumers’ 
areas of concern. 
While this training is relevant, it is only addressing one side of the story.  Furthermore, this 
training planned under SEAM Project is only for four Districts in Ruvuma Region and it is not 
known when this will be replicated in other regions. 
There is a need to put concerted efforts in using communications activities to fill this gap in 
the medium term. 
UNICEF 
UNICEF has supported a number of training programmes, particularly those of its own 
resource persons in Kyela and Magu Districts.   
It continues to be involved in the development of training modules for health care providers, 
particularly in the area of malaria management and prevention. 
UNICEF produced training modules for management of childhood illness in the year 2002.  
The manual focuses on various illnesses including malaria.  Since it is meant for clinicians it 
may therefore not be used for drug retailers or consumers for improving their knowledge.  
UNICEF is currently not engaged in malaria specific activities that focus on the drug retailer 
and the consumers. 
CEEMI 
During the meeting with CEEMI the information received was as follows: 
CEEMI’s main objective is to strengthen Zonal centres and CHMTs in terms of capacity 
building.  Training is delivered in a cascade manner starting from the Regional Medical 
Officers up to the dispensary level.  This kind of training is meant for prescribers/clinicians at 
the public and private levels and does not therefore address the shopkeepers. 
It has submitted a proposal for approval for education and training activities in the prevention 
and management of malaria in pregnant mothers in Tanga Region.  Training will be 
conducted at the Zonal Training Centre and will take the direction indicated above.    
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Apparently the training that has been conducted so far has not focused directly on drug 
retailers.  The community however gained from the private and public clinicians trained by 
trainers who were trained by CEEMI. 
Therefore, there is a need to urgently address the plight of the Part II retailers in so far as 
disseminating information to them on malaria is concerned.  The fall back activity is again 
communications.   
The mission was informed that a request is being made for funds to enable CEEMI to 
conduct training for drug retailers next year and that it will not be a one-off affair. 
CEEMI conducted a training workshop for journalists.  This strategy towards developing 
media relationship would be beneficial to NMCP with regard to damage limitation in case of 
side effects. (This is described in detail under communications strategy.) 
CHMTs 
CHMTs Training was very patchy.  It was actually one-off and was done on the back of 
training health workers after the change in first line policy.  There is no guarantee that it will 
continue and there are no records of how much has been done anyway. 
There is a big gap here and the only way out is to involve them in communications activities. 
Areas of Concern 
For the training to be effective: 
• It will involve a very large number of trainers and trainees.   
• It will have to be repeated frequently. 
• It will require a comprehensive package including refresher training, the monitoring of 
which would stretch the capacity of the District-level staff. 
• It will involve the development of training programmes, which will take District staff 
away from routine work, from which they are already away too much. 
• The Zonal Training Centres, which are also being proposed to take some of the 
training, will have to take more training load despite the fact that they are already 
burdened with heavy workload coupled with acute shortage of resource persons. 
Assessment of various training manuals on malaria has revealed that: 
• Training messages developed by some organisations are not consistent with the 
National Malaria Control Guidelines. 
 
Action Points  
NMCP should not be involved in training because there would not be adequate capacity 
to implement separate training programmes since training of drug retailers would also be 
done through ADDO training.  It should however encourage any donor who wishes to 
implement pilot projects on a small scale in order to learn more about what works to do. 
Communications would be a better way to change both consumer and retailer 
behaviour. 
NMCP should be involved in the approval of all malaria-training materials to avoid 
inconsistency in message delivery. 
A seminar should be given whenever there is a change of policy. 
11 Planning the Introduction of Artemisinin-Based Combination Therapy 
The Ministry of Health has indicated that they consider the use of SP as an interim strategy, 
and that a move to an Artemisinin-Based Combination Therapy (ACT) as first line drug is 
probable within the next three to four years.  The two ACTs being most actively considered at 
present are Artesunate+Amodiaquine and Artermether-Lumefantrine (Coartem™). 
There are three reasons why such a move is planned.  Firstly, resistance to SP is already 
present and expected to grow quite rapidly.  Secondly, ACTs have been shown to be highly 
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efficacious.  Thirdly, it is believed that the use of a combination regimen will reduce the rate 
of growth of drug resistance, so that for example the use of artesunate+amodiaquine will lead 
to slower development of amodiaquine resistance than the use of amodiaquine 
monotherapy. 
These advantages must be balanced against some important challenges in implementing 
ACT, not least of which is the cost.  With a predicted factory gate price of 1000/= to 3000/= 
per adult dose, there will be a more than ten-fold increase in the Government’s first line drug 
expenditure alone.  The price is unlikely to fall below 1000/= in the short to medium term due 
to the costs of extracting the active ingredient.  In addition it will be necessary to ensure 
appropriate use of these more complex drug regimens when dispensed by health facilities.   
It is also essential to consider the implications of ACT for the retail sector.  All the key issues 
raised so far in this report, concerning drug quality, labelling and instructions, product 
availability, consumer and retailer knowledge, and affordability, will be of equal or greater 
importance following a move to ACT.  However, a more immediate concern is that the 
implications for the private market should be incorporated now in choices about a future 
ACT-based policy.  It would be a grave mistake to design a new policy on the basis of the 
optimal choice for health facilities alone and only then to consider how it should be 
implemented in the private sector.   
The intended role of the retail sector must be taken into account from the outset in relation to 
three key choices about an ACT policy. 
11.1 Choice 1: Which combination should be chosen? 
Two issues need to be addressed here: firstly whether resistance will develop to the 
component drugs through their use as monotherapy in the retail sector, and secondly 
whether the ACT will be suitable for OTC retail sector distribution. 
11.1.1 Preventing Monotherapy with the Companion Drug 
Theory and experience from South East Asia indicate that the development of resistance to 
each component drug will be greatly reduced if they are used in combination, compared with 
their use as monotherapies.  However, if one of the drugs continues to be used widely as a 
monotherapy in the retail sector this impact is likely to be much diluted.  This could allow 
resistance to develop to that drug, reducing efficacy of the ACT and leaving the other 
component unprotected, even when used in combination.  Most attention has been focused 
on the dangers of monotherapy with the companion drug to the artemisinin derivative, rather 
than the artemisinin derivatives themselves.  This reflects the evidence that resistance to 
artemisinin derivatives has not developed in settings where they have been widely used as 
monotherapies, perhaps because of their very short half-life.  Moreover, although artemisinin 
derivatives are available in urban pharmacies as monotherapies in Tanzania, their retail price 
of 4000/= to 6000/= currently precludes widespread use.   
Two strategies could be employed to prevent the development of resistance to the 
companion drug:  
• Select a combination that does not include a widely available monotherapy e.g.  
Artermether-Lumefantrine, as Lumefantrine is not available as a monotherapy.   
• Select a combination that includes a currently widely available monotherapy and 
withdraw this monotherapy from the private market e.g. select artesunate-amodiaquine 
and withdraw amodiaquine monotherapies.  This should in theory be possible; the 
Government achieved a high degree of success in withdrawing chloroquine after it was 
abandoned as first line drug, with only very small quantities remaining in the market after 
one year.  However, experience might be different with a drug being withdrawn, not 
because it was no longer efficacious, but in order to protect it from resistance, especially 
if consumers were dissatisfied with the remaining alternatives on the retail market. 
11.1.2 Is ACT suitable for OTC retail sector distribution? 
An ideal first line drug would be suitable for distribution throughout the public and private 
sectors, to ensure maximum accessibility.  If it is intended that the ACT be used in the retail 
sector, a number of issues should be considered: 
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• Will the regimen be sufficiently simple? This will relate to the number and timing of 
doses, the availability of a co-formulated (rather than just co-packaged) product for all 
age groups, and any other special requirements (e.g. artermether-lumefantrine must be 
given with fat).  It will be important to conduct operational research prior to the policy 
change on adherence to the regimen, both when dispensed from formal facilities and 
when purchased from shops without a formal consultation.   
• Will the safety profile be suitable? Where drugs have not previously been used on a 
very wide scale, have potentially severe side-effects, or are contra-indicated for certain 
groups, such as pregnant women, they may be considered inappropriate for distribution 
without consultation with a health worker and/or the recording of patient records, 
effectively precluding OTC retail sector distribution. 
11.2 Choice 2: Should ACT be available to confirmed malaria cases only?  
To date the vast majority of suspected malaria cases treated in facilities and shops are 
diagnosed on the basis of clinical symptoms alone.  Microscopy is only available in a minority 
of facilities and a few private laboratories, and in government facilities its use is often 
reserved for suspected treatment failures.  However, in most of Tanzania at least half the 
suspected cases are not parasitaemic, and in some areas this share is much higher.   
It has been suggested that it would be appropriate to restrict ACT to patients with confirmed 
parasitaemia, possibly through the use of rapid diagnostic tests or “dipsticks”, which require 
less equipment and experience than microscopy.  This could potentially improve the 
management of both malaria and non-malaria cases, but the prime motive of introducing 
RDTs in conjunction with ACT would be to reduce the costs of using expensive drugs for 
aparasitaemic patients.  The actual cost savings will depend on the cost of the drugs, the 
cost of the RDT, the proportion of patients that are aparasitaemic, and whether the treatment 
protocol is adhered to in practice. 
If ACT were to be restricted to confirmed diagnoses across the public and private sectors, it 
would effectively be necessary to make it a prescription only medicine, i.e. officially available 
in Part I pharmacies only.  It could not be sold legally in general stores or Part II drug stores, 
severely restricting availability of the first line therapy in rural and peri-urban areas. 
11.3 Choice 3: Should you subsidise the combination in the private market? 
Substantially reducing the purchase price of artemisinin derivatives will require a concerted 
international effort.  Strategies currently under consideration by WHO and other international 
agencies include improving price information, bulk purchase, differential pricing for low 
income countries, voluntary or compulsory licences to manufacture drugs still on patents, 
and procurement and subsidy through a Global Malaria Drug Facility23.  The NMCP should 
use its lobby power to support such macro initiatives.  In the short to medium-term the cost 
price will remain high, and NMCP will be unable to unilaterally alter the price it faces.  Full or 
near-full subsidy of ACT in the public sector is therefore inevitable.  In view of the substantial 
increase in the retail price, one needs to consider whether subsidies should also be provided 
for ACT in the retail sector.   
The two options of an unsubsidised or subsidised private market are explored below. 
11.4 Option 1: Unsubsidised private market 
As discussed in section 10.1, a retail price of 300/= to 500/= for an adult dose with the 
current first line drug is unaffordable to many people.  Replacing SP with an ACT costing 
around five times as much would effectively exclude all but the wealthiest citizens.  One 
would expect to see some shift in utilisation from the private to the public sector, but 
widespread use of shops is likely to continue because of their far greater accessibility and 
 
23 RBM Partnership Meeting on Improving Access to Antimalarial Medicines, 30th September-2nd October 2002, 
Draft Report, January 2003, Malaria Control Department, WHO, Geneva. 
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convenience.  Treatment for the vast majority continuing to use shops will therefore inevitably 
be contrary to the national treatment guidelines. 
The Government may choose to accept this situation, especially while efficacious 
monotherapies are available.  If they do, they should note that it will remain essential to 
provide treatment guidelines and an appropriate communication package to ensure 
appropriate use of these monotherapies in the retail sector.  This will lead to a situation 
where there are effectively two sets of treatment guidelines, one for facilities and one for 
shops, adding to the complexity of the overall policy. 
With an unsubsidised private market, the highly subsidised public provision of a drug with a 
high retail sector value will provide a powerful incentive for theft (See Box 3) from the public 
sector and or forgery into the whole market.  Although a number of measures have already 
been taken to prevent theft from drugs kits distributed to peripheral facilities, these may be 
insufficient to prevent the development of a black market for a product that is both highly 
subsidised and highly valued by consumers.  This in turn would make it extremely difficult to 
monitor utilisation. 
 
Box 3: Faking Artesunate in Cambodia 
The Artesunate pack shown in Figure 15 shows the genuine hologram label enlarged on the 
right.  It also shows an example of a fake hologram that has been found on other packs of 
Artesunate.  Although seen side by side the fake is obvious it does illustrate the 
sophistication and lengths to which fakers will go when the price of the product is high 
enough to justify the effort. 
Figure 15 
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  Source: Jan Rozendaal, M.Sc., Ph.D 
Faking of drugs in Tanzania was reported to us.  It was alleged that aspirin is coated with 
sugar and then sold as quinine.  There is no doubt that wide use of ACT will encourage the 
fakers to extend their market, so it only a matter of time before the Cambodian experience is 
repeated in Tanzania. 
11.5 Option 2: Subsidised private market 
The alternative option would be to extend subsidies to the retail sector.  The overall cost of 
the ACT policy would dramatically increase, although the size of the increase is difficult to 
predict, depending on both the percentage subsidy, the elasticity of demand, and the 
administrative costs of delivering the subsidy.  The subsidy would need to cover a high 
proportion of the cost of ACT to have a significant impact on demand, probably bringing it 
down to below the level current price of SP.  If the subsidy is not great enough, even 
subsidised ACT could be considered unaffordable by the poorest groups.  As a result the 
benefit of the substantial increase in public funding would be captured by the relatively well-
off groups. 
Increased cost would not be the only problem.  There would also be a range of operational 
challenges to address.  Although many people have called for the use of private sector 
subsidies for ACT, there is no consensus on how these should be implemented.  A range of 
Antimalarial Drugs in the Private Sector in Tanzania                                  Malaria Consortium 
49  
                                                
options exist, which can be distinguished by whether they are targeted or universal 
subsidies, and the delivery mechanism used. 
11.6 Targeted versus Universal Subsidies 
Universal or generalised subsidies are potentially available to all members of a community, 
whereas targeted subsidies aim at increasing the demand of particular groups in society.  A 
key advantage of targeting is that it can reduce the cost of the subsidy (or increase the 
amount of subsidy that can be provided to recipients).  It can also be used as a tool to 
increase equity (by transferring resources to poorer groups), and efficiency (by channelling 
resources to those most able to benefit, and by avoiding subsidising people who would have 
purchased at an unsubsidised price)24.   
The target group may be selected on the basis of biological or economic characteristics.  The 
most biologically vulnerable groups for malaria in Tanzania are generally considered to be 
pregnant women and children under five, although in epidemic prone areas all age groups 
are non-immune.  Targeting a biologically vulnerable group would not make sense if the aim 
was to achieve high coverage of ACT across the whole population.  However, the desired 
impact on the growth of drug resistance should be achieved even with partial coverage, as 
long as monotherapy with the component drugs is not widespread among the rest of the 
population.  Targeting on the basis of economic characteristics is fraught with the difficulties 
of finding a simple and reliable way to identify the poorest groups.  Moreover, in the case of 
ACT this may be inappropriate if the majority of the population would find it unaffordable.   
11.7 Subsidy Delivery Mechanism 
Several potential delivery mechanisms exist, which introduce the subsidy at different levels of 
the distribution chain: 
• Subsidise at the level of manufacturers and importers by providing a fixed payment 
or tax break on each unit distributed.  This would by default imply the use of a universal 
subsidy.  Some strategy of retail price maintenance might be required to ensure that the 
lower price was passed all the way down the distribution chain.   
• Subsidise at the level of a national distributor, which could purchase from a range of 
potential manufacturers and importers at the market rate, and sell on to wholesalers and 
retailers at a substantially lower price25.  The products could be sold on as they were, 
with the organisation acting merely as a procurement agency, or could be repackaged as 
a single socially marketed brand, and promoted under this brand name.  The subsidised 
products may be supplied on a universal basis, or targeted to particular groups through 
the style of packaging, marketing or distribution channels used in a social marketing 
strategy.  Again retail price maintenance would be required to ensure the lower price was 
passed on.   
• Subsidise at the level of the consumer/retailer through a voucher system.  Targeted 
and untargeted vouchers systems have been used in the delivery of education, food and 
public health commodities, including treatment for sexually transmitted infections, and 
other reproductive health care26.  Tanzania has experience with a small-scale voucher 
scheme for ITNs in Kilombero and Ulanga Districts and is planning to begin to roll out a 
nationwide scheme in 2003.  Vouchers will be provided at antenatal care visits in order to 
target the most biologically vulnerable groups of pregnant women and young children.  
 
24 Worrall, E., V.  Wiseman and K.  Hanson (forthcoming).  Targeting of Subsidies for Insecticide Treated 
Mosquito Nets.  London School of Hygiene & Tropical Medicine, Health Economics and Financing Programme 
Working Paper. 
25 In the case of artemether-lumefantrine it would only be necessary (and possible) to subsidise the single product 
on the market because it is still under patent. 
26 Gorter, A. C.  (2003).  Review paper on evidence for using competitive voucher schemes and related methods 
for ensuring young people have access to health service interventions designed to prevent or provide care for 
HIV/AIDS. Background paper prepared for the "Consultation on the health services response to the prevention 
and care of HIV/AIDS among young people." 
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The vouchers will cover a substantial proportion of the retail price and will be redeemable 
in any shop.   
While a comparable voucher approach is conceivable for ACT27, it would be complicated 
by a number of factors.  Firstly the number of episodes experienced by the target group 
would be difficult to predict, and would probably necessitate a “book” of vouchers, rather 
than a single one.  Secondly vouchers for ACT would be highly transferable between 
individuals (meaning that they could be used by any family member or sold to other 
people, and are therefore less likely to “stick” to the target group), and between products 
(meaning that shopkeepers could redeem the vouchers against other products).  Thirdly, 
distributing vouchers at health facilities would be unlikely to reach the groups that do not 
have good access to facilities, and are most in need of vouchers for private sector drugs.  
This would necessitate the use of alternative distribution mechanisms, such as 
community leaders or NGOs.  Finally, the national policy is to encourage these 
biologically vulnerable groups to visit a facility for treatment rather than a shop, and 
providing vouchers to be redeemed in shops would send a confusing message.  
However, the experience of the ITN pilot should be reviewed to assess whether there are 
any lessons to be drawn for ACT.   
In summary, the private sector must be considered at an early stage in all decisions made 
about an ACT policy.  The Government needs to take a proactive stance, deciding what 
coverage with the ACT first line they would like to achieve, which drugs should be available 
in the retail sector, and at what price, and then design a policy and set of interventions to 
achieve these goals.   
 
Action Points  
Decide how to make ACT available to the public and private sector. 
Identify mechanisms to make it affordable. 
Decide on a date for its introduction. 
 
12 Options for Implementation and funding  
12.1 National level activities 
The Private sector is an important partner in the provision of antimalarial drugs to most of the 
rural population.  The Ministry of Health, through Health Sector Reforms, recognizes and 
promotes private sector involvement in the delivery of quality health services.        
Ensuring the quality of antimalarial drugs that are distributed, and appropriate delivery and 
utilization by the end user are key areas that would contribute greatly towards reducing 
development of severe disease and mortality due to malaria.  However, the quality of some 
antimalarial drugs available in the different outlets is questionable.  Often the price of such 
drugs, most of them illegally distributed and unregistered, is lower than registered ones and 
therefore easily accessible to the majority of the poor rural population.  Eventually the 
parasites might develop resistant strains and also the disease condition might turn into 
severe form.  Conformity in dosing information by manufacturers with National Guidelines is 
critical to avoid confusion and under-dosing by the public.  Optimal packaging and enclosing 
adequate information about correct drug use is essential to improve understanding by the 
consumer without underscoring the language used by the majority of the population.   Lack of 
                                                 
27 Vouchers for ACT were tried in Myanmar where a subsidy was introduced for mefloquine through the provision 
of a voucher, given to care-seekers with the artemisinin prescription, and redeemable at specific outlets.  
However, post intervention, only 3.6% of patients chose to redeem their voucher, and all of those doing so were 
being treated at the hospital where both drugs were available.  None of the other patients were prepared to put up 
with the inconvenience of going to another outlet to redeem the voucher (Shwe et al., 1998).  This experience 
would not be directly relevant to a potential voucher system in Tanzania where the voucher would be likely to be 
for a coformulated or at least co-packaged product.   
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standard measurement for various syrups available in the different drug outlets is a serious 
omission that might cause under or overdosing practices by most rural caretakers.   
The success of malaria case management mainly depends on many factors, including quality 
assurance of pharmaceuticals for adequate clinical cure of malaria patients.  A robust 
registration procedure for pharmaceutical products, manufactured in the country or imported,  
which addresses the above-mentioned concerns, and routine quality assurance monitoring, 
backed by effective legislation, must be guaranteed in order to protect consumers against 
counterfeit or substandard drugs. 
12.1.1 Ensuring quality antimalarial drugs 
The Pharmacy Board has the mandate to ensure drugs sold in the country conform to the 
laws and regulations set.  The Pharmacy Board, in collaboration with partners, has started to 
address some of the deficiencies in terms of availability of registered and quality drugs 
through enforcement of GMP, introduction of Minilab and introduction of the ADDO scheme.  
The National Malaria Control Programme should be proactive, have an advocacy role and 
work in close collaboration with the Pharmacy Board to discuss and follow up above-
mentioned issues that support malaria interventions.  Furthermore it will be necessary to 
strengthen and enforce supervision at all levels to also critically deal with drug stock 
management. 
12.1.2 Promote marketing strategies consistent with the national guidelines, 
packaging and labelling 
It will be necessary for the Pharmacy Board to review regulations for registration to include 
recommendations made on the above-mentioned issues.   
Effective utilization of existing structures, for example the Tanzania Association of 
Pharmaceutical Industry (TAPI) and Tanzania Pharmaceutical Manufacturers Association  
(TPMA), to promote marketing strategies that are consistent with national policy and 
recommendations, including those on packaging and on enclosing adequate information 
about drug use is recommended.  Such fora are also opportunities to discuss other pertinent 
issues like drug stock management. 
12.2 Implementation of Communication strategy  
The intent of the Communication Strategy is to promote positive behavioural change on 
appropriate delivery of antimalarial drugs available for sale in duka la dawa baridi and their 
use by the rural community.   
The Government recognizes that advocacy and information for behaviour change are 
fundamental to improvement of the health status of the people.  It has committed itself to 
intensifying communication efforts through increased information for behaviour change, 
political support, and collaboration with other partners, to ensure that all Tanzanians have 
access to accurate malaria control information.  Effective delivery of the communication 
strategy is important to get the desired outcome.  Experience from other programmes show 
that apart from mass media using radio, television, posters, leaflets etc, face to face contact 
is critical for attainment of behaviour change.  Persistent behaviour change also requires 
repeated actions from time to time especially at the community level.   Concerted efforts that 
are sustainable will be required for effective implementation of the strategy from the National, 
district and community level to effect the required behaviour change.  Experience on the 
subject matter of commercial /social marketing and community based organizations will be 
exploited for effective implementation of the strategy through contracting out.   
12.3 Source of funding 
12.3.1 Public funding 
The Government of Tanzania and its partners are committed to malaria control.  Also through 
the Sector Wide Approach, funding of Council Health plans has also increased significantly.  
The Strategy therefore should be integrated in the Medium Term Expenditure Framework at 
the National level.  Council Health Management Teams would be encouraged to also include 
relevant activities, including supervision in their Comprehensive Council Health Plans. 
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12.3.2 Global Fund to fight AIDS, Tuberculosis and Malaria 
The National Malaria Control Programme could use other available opportunities (such as 
the Global Fund) for effective implementation of the strategy, and particularly in conjunction 
with the introduction of Combination Therapy (CT) in Tanzania.  The World Health 
Organization advocates for combination therapy because of high cure rate and delay in the 
development of resistance in either of the drugs involved in the combination.  Unless the 
existing practices by both providers and communities change, the effectiveness of CT 
strategy will not last long.  Adequate funds made available through the Global Fund could be 
used for effective implementation of a communication strategy as a prerequisite for effective 
introduction of CT in the country.      
12.3.3 Bilateral funding 
Based on comparative advantages, funds for implementation of the communication strategy 
at the National and District level could also be secured from other sources such as bilateral 
organizations, in addition to their contribution to the Basket fund or from those not 
participating in basket funding. 
 
13 Work plan and cost estimates for the next two years 
A draft work plan is shown in Figure 16.  It is based on the following list of action points.  It 
shows calendar time during which tasks should be completed.  In some instances, for 
example task 11 “Test all batches”, the task is to set up a procedure that will then continue 
indefinitely. 
The major task needed is to conduct a detailed communications assessment.  This should be 
carried out by a specialist consultant and should result in detailed plans of how an integrated 
communications package could be introduced to enable the private sector to become more 
effective at supplying quality antimalarials to the population.  That consultancy should include 
detailed cost estimates and a terms of reference so that contractors can be invited to bid for 
the task of carrying out the identified strategies.   
ToRs of consultants are shown in Appendix 13. 
There are many tasks in the work plan for which NMCP will inevitably be responsible.  It was 
clear to the team that NMCP is seriously under-staffed and does not have the capacity or 
authority at the moment to meet these responsibilities. Unless there is significant investment 
in staff and resources at NMCP then progress on strengthening the private sector will be very 
limited. 
The cost of a major investment in promoting the private sector will be substantial.  PSI plans 
to spend in the order of two million dollars a year on promotional activities; a national 
communications package is likely to cost substantially more than this. 
Unless there is a greater commitment by the MoH to strengthen the delivery mechanisms for 
malaria control in the private sector, malaria will remain a major cause of morbidity and 
mortality in the young children of Tanzania. 
 
Work plan tasks (number in brackets refers to the ID number on the Gantt chart) 
10) 3.1 Ensuring Quality of Registered Antimalarials at Factory Gate/ Point of Entry 
11) As well as testing imported antimalarials, government capacity should be established to 
test all batches of locally manufactured antimalarials. 
12) Expand the range of products tested at minilabs.   The inclusion of amodiaquine and 
SMP tablets in routine quality control checks at ports of entry must be prioritised.   The 
potential to add syrup and injectable antimalarial formulations to the products tested in mini-
labs should also be investigated.    
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13) Antimalarials not tested by minilabs should be tested routinely at NDQCL.   While waiting 
for appropriate methods to be developed for other antimalarials, these products should not 
go completely unchecked.   Capacity exists at the NDQCL to test all of these drugs.   While it 
may not be possible to test every batch produced or entering the country, batches should be 
sampled at the factory gate or port of entry, and the samples transferred to the NDQCL on a 
routine basis.   In Dar es Salaam in particular this should be relatively easy to implement, as 
the port of entry testing for Dar es Salaam International Airport is currently done at the 
NDQCL. 
14) 3.2 Preventing Distribution of Unregistered Antimalarials 
15) Print registration number on inner and outer packaging.   As drugs in blister packs often 
become separated from their outer packaging/box before use, it would be prudent to require 
that the registration number be printed on both the inner and outer packaging of the product.    
16) Checklist of registered products.  A clear checklist of all currently registered general sale 
products should be prepared by the Pharmacy Board.   The list should be clearly presented, 
and ordered alphabetically by brand name, so that any product found in a Part II Drug Shop 
or general store can quickly be checked against the list.   The list should be distributed to all 
drug inspectors, wholesalers, and retailers.   It would be particularly beneficial for health 
assistants, who are the only inspectors of general stores, but do not have expertise in 
pharmaceuticals and are often unable to judge whether the drugs they encounter are 
permitted.  It could also be produced in the form of a poster for display in Part II outlets to 
enable consumers to check the registration of products before they buy.   The list must be 
reprinted and redistributed regularly to ensure that it is up-to-date. 
17) Education campaign on registration.  The message that you cannot be sure of the quality 
of any unregistered product must be clearly conveyed to retailers and consumers.  This 
should form an important component of the communication package, in tandem with 
information on how to find out which products are registered.   
18) 3.3 Ensuring the Maintenance of Drug Quality during Distribution and Sale 
19) Working with wholesalers to improve their practices.  The Pharmacy Board is working 
with local manufacturers to assist them in implementing internal quality assurance.  A similar 
relationship should be established with the main drugs wholesalers, perhaps through one of 
the professional associations (Pharmaceutical Society of Tanzania (PST) or Tanzanian 
Association of Pharmaceutical Industries (TAPI)).  The interaction should focus on the 
importance of good stock management and storage, packing for distribution, knowledge 
about regulations and drug registration in particular.  As with the manufacturers, a timetable 
for improved practice should be established, with strict sanctions if these targets are not met.   
20) Eliminating tins of antimalarials from Part II drug shops and general stores.  The 
regulations banning the sale of drugs from tins should be strictly enforced for antimalarials.  
The issue should be highlighted with retail drugs inspectors, and wholesalers and retailers 
should be alerted to the intended clampdown and its rationale.  The Pharmacy Board could 
also work with local manufacturers to encourage them to produce all their antimalarial tablets 
in blister packs.  A concern is that this may increase the cost of antimalarials to consumers if 
the cost per tablet is lower in bulk packs, although tablets in tins and blisters are frequently 
sold for the same price in retail outlets.  
 21) 3.4 Post Marketing Surveillance 
22) Abandon post marketing surveillance role for minilabs.  We recommend that random 
routine testing of drugs in retail outlets in the regions be abandoned.  The activities of 
minilabs should be focused on checking the quality of drugs at the top of the distribution 
chain (factory gate or point of entry).  The energy of inspectors at national and regional level 
should be invested in ensuring that the distribution chain meets the operational standards for 
appropriate transportation and storage.  Such a quality assurance system should then 
guarantee that only good quality drugs enter the distribution chain, and that their quality is 
maintained until the point of retail sale. 
Malaria Consortium  Antimalarial Drugs in the Private Sector in Tanzania                 
 54
In some cases, there was no dosing information available on the tubs/tins, hence the 
retailers are likely to underdose or over-dose the patient.  Besides, some outlets kept loose 
tablets in tins of drugs other than those of antimalarials with different dosage regimens.  This 
scenario further aggravates the matter. 
23) 4 Appropriate and understandable labelling and instructions 
24) Ensure that the products sold in Part II shops are sold in their original packs as closed by 
the manufacturers, as required by the PB guidelines for Part II poisons, to avoid use of wrong 
labels for the right drug. 
25) By next registration i.e. 2004, only amodiaquine, SMP and SP products conforming with 
the following regulations will be registered: 
Inclusion of dosing information in Kiswahili as a requirement for registration at least for 
antimalarials.  This will enable all Tanzanians to follow dosage instructions easily, 
communicate without message distortion, be motivated and encouraged to read the 
instructions on the label. 
26) All dosing information to conform to National Malaria Treatment Guidelines.  This will 
eliminate confusion over SMP and amodiaquine dosage regimens.   
Manufacturers should include measuring devices in all syrups/mixture packages. 
Generic names must be in large clear letters (larger than brand name). 
Extra cards must be inserted in packs with user-friendly dosing instructions. 
27) 5 Increasing the Availability of General Sales Antimalarials 
28) Effective communication of drug regulations.  It is essential that all those involved in the 
retail drugs market are clear about which types of drug can be stocked in general stores, and 
which brands are registered (or licensed for distribution) in Tanzania.  This information 
should form a key part of the communication package for consumers, retailers, wholesalers, 
national distributors and local manufacturers (see section 8).  Particular emphasis should be 
placed on reassuring general retailers in remote areas with few or no drug stores, and 
encouraging them to stock SP and amodiaquine. 
29) Encouraging national distributors to stock and promote SP and amodiaquine.  Individual 
retailers and sub-wholesalers have very little control over the products they stock because 
the product range is effectively determined by a small number of national distributors.  
Discussions should be held with the national distributors to clarify the regulations and 
encourage them to include SP and amodiaquine.  Distributors should be encouraged to stock 
only SP and amodiaquine products appropriate for general retailers (i.e. blister packed with 
clear labelling and dosing instructions in Swahili).  An alternative (or complementary) 
approach would be to work through the PSI distribution network, which bypasses the national 
distributors by delivering products such as Ngao (insecticide re-treatment kit for mosquito 
nets) and Salama condoms direct to large wholesalers.   
30) Encouraging manufacturers to produce smaller bulk packs.  Blister packed SP and 
amodiaquine are generally sold wholesale in boxes of 75 tablets (25 packs of three tablets) 
for Tsh 1700-3000 for amodiaquine, and Tsh 3500-4500 for SP.  The introduction of smaller 
bulk packs (e.g. 30 tablets per pack) should encourage more small retailers with limited 
capital to stock antimalarials. 
Link with communication package for consumers.  These interventions on the supply side will 
be complemented by the communication package for consumers to encourage early 
treatment of febrile illness with appropriate antimalarials and to raise awareness about local 
sources of antimalarials. 
31) 6.  Controlling availability of restricted products 
32) Clear alphabetical list of Part II registered brands should be made available to all Part II 
and general outlets, pharmaceutical and general wholesalers and those involved in their 
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inspections (Regional Pharmacists, District Pharmacists, CHMTs and Health Assistants, so 
that they can quickly check and ascertain if the products in stock are registered. 
Information to consumers and inspectors should highlight that quality of unregistered drugs is 
not guaranteed and that checking to ensure that the drugs are registered is in the interest of 
the consumers. 
Major efforts should not be put into removing antimalarials like artemisinin derivatives and 
quinine from Part II outlets.  This would require regulatory effort and undermine the fact that 
government patients are often sent to buy these drugs from Part II outlets, and in any event 
ADDOs are to be allowed to stock both quinine tablets and injections.  Moreover their use is 
unlikely to be highly damaging to public health, so putting regulatory effort to remove them is 
unlikely to be cost effective use of resources. 
33) Review the magnitude of the problem with regard to disposal of syringes and needles. 
34) 7. Safety of Private Diagnostic Laboratories 
35) Close laboratories which are in the same buildings as pharmacy outlets. 
36) Educate the inspectors to recognise unsafe practices. 
37) Introduce stringent inspection of private laboratories.  
38) The owners of Part II outlets should not own laboratories. 
33) Conduct a safe parenteral procedure survey of laboratories and Part II pharmacies. 
39) 8.  Ensuring that Consumers have adequate knowledge 
40) Use commercial marketing strategic approaches described herein to be run by outside 
agencies or PSI. 
41) Use road shows to be conducted in each area on an annual basis (not one-off push).   
42) Integrate these shows with other media in a co-ordinated and sustained campaign. 
43) Both Part II pharmacy workers and general shopkeepers must be involved in the road 
shows.  They can be brought in before the road show is presented to the public to be given 
specific training and then involved in the road show, so that the public see them as being 
knowledgeable and a part of the health care system. 
44) Redesign NMCP IEC materials to include Amodiaquine tablets and syrup as well as SP.  
A brochure and price list of activities and materials should be sent to the Districts.  They can 
then order the materials through NMCP and pay for them out of the basket fund. 
45) Laminate IEC posters for Part II and general shops (paper posters are counter productive 
because they are easily destroyed),  
46) Develop and produce “top pocket” size laminated dosing cards and promotional material 
like T-shirts, kangas, caps etc. for consumers.   
47) Work closely with manufacturers and encourage them to step up their poster and 
appropriate dosing campaigns. 
48) Work with CEEMI to cultivate and sustain media relationship with the aim of creating an 
avenue for sustained publicity and editorials as well as damage control. 
49) 9 Making General Sale Antimalarials Affordable to the Majority 
50) Strategies should be adopted to push down mark-ups where they are excessive by 
providing information to consumers and increasing competition in the market: 
51) Publicity campaign to push down SP prices.  A key component of the communication 
package should be increased awareness of appropriate prices to pay for the first line drug, 
e.g.  “don’t pay more than 200/= for 3 tablets of SP”.  This must be combined with IEC 
materials and packaging that indicates clearly which brands fall under which generic 
category.  The publicity campaign should include posters giving recommended retail prices 
for general sale antimalarials.  This is already done for cigarettes.  Although most 
manufacturers or importers provide distributors with schedules of recommended wholesale 
and retail prices, these are treated as suggestions only, and are not enforced.  Retailers are 
Malaria Consortium  Antimalarial Drugs in the Private Sector in Tanzania                 
 56
generally totally unaware of the recommendations.  This could be addressed by printing 
recommended prices on product packaging (as PSI do with their socially marketed products), 
but commercial manufacturers are unwilling to take this step unilaterally, in case it made their 
products less attractive to retailers.  An alternative would be to produce generic advertising 
materials listing recommended prices for SP.  The main East African manufacturers may be 
willing to include their brand names on the poster in return for the additional publicity they 
would receive, especially as such price maintenance is likely to increase their profitability by 
increasing sales at a constant factory gate price. 
52) Encourage more general shops to stock SP and amodiaquine.  Expanding the range of 
shops stocking these antimalarials should increase competition and drive down prices where 
mark-ups are high (see section 9.1). 
53) Reducing Government facility prices for SP and amodiaquine.  In many government PHC 
facilities all services are provided free.  However, some districts have begun to introduce 
“cost-sharing” for drugs including first and second line antimalarials.  In a Kilombero 
dispensary patients were charged 300/= for an adult dose of SP (and in addition were 
required to pay a 200/= consultation fee).  This represented a huge mark-up of 825% on the 
discounted price at which the drugs were purchased by MSD, apparently a deliberate 
strategy to allow cross-subsidisation of other more expensive drugs, such as Benzyl 
penicillin.  This is an entirely inappropriate strategy for the first line antimalarial in 
government facilities, and eliminates the potential to exert downward pressure on prices in 
the retail market.  In view of the additional travel and waiting costs incurred by patients 
visiting health facilities, Government price schedules should be revised to ensure that the 
total direct cost of treatment is at a minimum not more expensive than care from shops, and 
is preferably substantially cheaper.   
54) 10  The role of training 
55) NMCP should not be involved in training because there would not be adequate capacity 
to implement separate training programmes since training of drug retailers would also be 
done through ADDO training.  It should however encourage any donor who wishes to 
implement pilot projects on a small scale in order to learn more about what works to do. 
Communications would be a better way to change both consumer and retailer behaviour. 
NMCP should be involved in the approval of all malaria training materials to avoid 
inconsistency in message delivery.  
A seminar should be given whenever there is a change of policy. 
56) 11 Planning the Introduction of Artemisinin-Based Combination Therapy 
57) Decide how to make ACT available to the public and private sector. 
58) Identify mechanisms to make it affordable. 
59) Decide on a date for its introduction. 
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Figure 16    Outline Work Plan 
ID Task Name Duration Resource Names
1 Report processing and discussion 0 days 
2 Circulate report to stakeholders 21 days NMCP 
3 Meeting to discuss report  1 day NMCP 
4 Consultative meeting with Mfr, Importers etc 1 day NMCP 
5 Agree courses of action based on report 5 days MoH/PB/NMCP
6 organise consultancy on  comms strategy 60 days NMCP 
7 tender documents for comms work 10 days NMCP 
8 process and accept comms consultancy 36 days NMCP 
9 carry out comms consultancy 50 days consultant 
10 3.1 Ensure Drug Quality 0 days 
11 Test all batches 60 days PB 
12 Include amodiaquine test at Minilabs 140 days PB 
13 NDQCL testing 120 days PB 
14 3.2 Unregistered Antimalarials 0 days 
15 Print registration number 180 days PB/Mfr. 
16 Checklist of registered products 90 days PB/NMCP 
17 Education on unregistered drugs 180 days NMCP/Districts
18 3.3 Drug Quality during distribution 0 days 
19 Work with wholesalers 180 days NMCP 
20 phase out bulk tins 365 days PB/NMCP 
21 3.4 Post marketing surveillance 0 days 
22 stop random testing  60 days PB 
23 4 Appropriate labelling 0 days 
24 Appropriate labelling 90 days 
25 keep in original packs 90 days NMCP/Part I,II and shops
26 New requirements for registration 60 days PB 
27 5. Increase availability through shops 0 days 
28 Effective communication of regs 90 days NMCP 
29 Promote SP & Amodiaquine 120 days PB/NMCP 
30 Produce smaller bulk packs 180 days manufacturers/NMCP
31 6. Control of Part II drugs 0 days 
32 Stocking Part I drugs at Part II pharmacies 120 days PB/NMCP/Districts
33 Safety of Parenteral procedures 120 days NMCP 
34 7. Safety of Private  Laboratories 0 days 
35 close labs in Part II pharmacies 180 days Districts 
36 Educate inspectors 90 days NMCP/Districts
37 Improve inspection 180 days Districts 
38 Lab owners 365 days PB/NMCP 
39 8 Consumer Knowledge 0 days 
40 commercial marketing 365 days Contractor/NMCP
41 Develop road shows 120 days contractor 
42 Road Shows 270 days contractor 
43 Involve PartII and general shops 90 days contractor 
44 Redesign IEC material 120 days contractor 
45 Laminated Posters 31 days contractor 
46 Promotional materials 90 days contractor 
47 Manufacturers posters 90 days Mfrs/Contractor
48 Work with CEEMI 270 days contrator/NMCP/CEEMI
49 9 Make antimalarials affordable 0 days 
50 Develop strategies to reduce prices 60 days PB/NMCP 
51 Promote the strategy 90 days NMCP/Districts
52 Encourage shops to stock SP & AQ 90 days NMCP/Districts
53 Reduce price of SP in Govt. facilities 90 days Districts 
54 10 Role of training 0 days 
55 NMCP start  to approve all training for consistancy 0 days NMCP 
56 11 Planning the Introduction of  ACT 0 days 
57 Strategy for introduction 120 days NMCP/PB 
58 Make ACT affordable 120 days MoH/PB/NMCP
59 Decide date for introduction 30 days NMCP/PB 
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